Autoimmune disease
MONDO:0007179A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to their own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).
Also known as: autoimmune disease, autoimmune disease or disorder, autoimmune disorder, disease, autoimmune, autoimmune hypersensitivity disease, hypersensitivity reaction type II disease
3535 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 653 trials in this tab.
-
Community leaders step up to boost COVID shots in black rheumatic patients
⭐️ VACCINE ⭐️ OngoingThis study tests whether training popular community leaders to share vaccine information can increase COVID-19 booster shots among Black individuals with rheumatic conditions like lupus. About 60 people will take part, including leaders and their social network members. The goal …
Phase: NA • Sponsor: Northwestern University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
Withdrawn study sought to boost RA remission with education and team care
Disease control TerminatedThis study was designed to test whether a combination of an educational booklet, team-based care from a rheumatologist, physical therapist, and psychologist, plus nurse-led phone calls and home symptom tracking, could help more Hispanic adults with rheumatoid arthritis achieve re…
Phase: NA • Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New shot could ease droopy eyelids in rare muscle disease
Disease control OngoingThis study tests a drug called efgartigimod for adults with ocular myasthenia gravis, a condition that causes eye muscle weakness like droopy eyelids or double vision. About 141 people will receive either the drug or a placebo for 7 weeks, then everyone gets the drug for up to 2 …
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Nasal spray could tame brain inflammation in progressive MS
Disease control OngoingThis phase 2a trial tests a nasal spray called foralumab in 54 people with non-active secondary progressive multiple sclerosis (SPMS). The spray contains an antibody that aims to calm overactive immune cells in the brain. Participants will receive either a low dose, a high dose, …
Phase: PHASE2 • Sponsor: Tiziana Life Sciences LTD • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New inhaled therapy aims to slow lung scarring in progressive fibrosis
Disease control OngoingThis study tests an inhaled form of pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their usual care. T…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New study puts omnipod 5 to the test in Real-World diabetes management
Disease control OngoingThis study is testing the Omnipod 5, a tubeless insulin pump that automatically adjusts insulin delivery, in real-world settings for people with type 1 diabetes. About 304 participants aged 2 and older will use the system for the first time. Researchers will track blood sugar con…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hip implant aims to cut repeat surgeries
Disease control OngoingThis study is testing a new hip implant called the OR3O Dual Mobility System in 177 people who need hip replacement surgery. The goal is to see if the implant is safe and lasts longer without needing another surgery. Researchers will follow participants for up to 10 years to chec…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Smart dosing strategy could keep rheumatoid arthritis under control
Disease control OngoingThis study compares two ways of managing rheumatoid arthritis in people taking adalimumab. One group gets standard care, while the other has their dose adjusted based on regular blood tests that measure drug levels and antibodies. The goal is to see if personalized dosing helps m…
Phase: PHASE4 • Sponsor: Diakonhjemmet Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug shield kidneys from lupus damage?
Disease control OngoingThis phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…
Phase: PHASE1, PHASE2 • Sponsor: Hospital Civil Juan I. Menchaca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New shot aims to shield celiac patients from gluten damage
Disease control OngoingThis study tests an injectable drug called TEV-53408 in 50 adults with celiac disease who follow a gluten-free diet. Participants will be exposed to small amounts of gluten to see if the drug can prevent intestinal damage. The trial is placebo-controlled and lasts about 86 weeks,…
Phase: PHASE2 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug PIT565 enters human testing for rheumatoid arthritis
Disease control OngoingThis early-phase trial is testing a new drug, PIT565, in 57 adults with rheumatoid arthritis. The main goal is to check if the drug is safe and how the body processes it. Researchers will monitor side effects and measure drug levels in the blood.
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New lupus drug PIT565 enters human safety trials
Disease control OngoingThis early-stage study tests a new drug called PIT565 in about 54 people with active lupus who have not gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Participants will receive increasing doses of the drug and be…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to help type 1 diabetes patients keep making insulin
Disease control OngoingThis phase 2b trial tests frexalimab, an antibody that calms the immune system, in 192 adults and teens newly diagnosed with type 1 diabetes. The goal is to see if it can preserve the body's ability to produce insulin, reducing reliance on injections. Participants receive frexali…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could changing carbs and adding fiber improve blood sugar in type 1 diabetes?
Disease control OngoingThis study explores how different amounts of carbohydrates and a fiber supplement called inulin-FOS affect blood sugar control in adults with type 1 diabetes. Participants will try three two-week diets: one with 30% carbs, one with 50-55% carbs, and one with 50-55% carbs plus inu…
Phase: NA • Sponsor: Hacettepe University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Daily injection shows promise for Long-Term control of rare muscle disease
Disease control OngoingThis study tests the long-term safety and effectiveness of zilucoplan, a daily injection, in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. About 200 participants who completed a prior zilucoplan trial will receive the drug for an extend…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New program helps older diabetics and caregivers share glucose data to improve health
Disease control OngoingThis study tests a program called Share plus for adults aged 60+ with type 1 diabetes and their care partners. The program helps them better use continuous glucose monitor data together. Researchers want to see if it improves blood sugar control and reduces diabetes-related stres…
Phase: NA • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New insulin icodec study aims to improve diabetes control
Disease control OngoingThis study observes how well insulin icodec controls blood sugar in 245 people with type 1 diabetes who have never used it before. Participants take the insulin as prescribed by their doctor, and researchers track changes in HbA1c and treatment satisfaction over about 22 to 30 we…
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a TB vaccine tame type 1 diabetes in kids?
Disease control OngoingThis study is testing whether giving the BCG vaccine (normally used for tuberculosis) twice, four weeks apart, can improve blood sugar control and reduce insulin needs in children aged 8 to 17 who were recently diagnosed with type 1 diabetes. The trial involves 100 participants a…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a TB vaccine help kids with type 1 diabetes?
Disease control OngoingThis study tests whether giving the BCG vaccine (traditionally used for tuberculosis) twice, four weeks apart, can help children aged 8 to 18 with type 1 diabetes. The goal is to see if it improves blood sugar control, reduces insulin use, and lowers the risk of dangerously low b…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in large trial
Disease control ENROLLING_BY_INVITATIONThis study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill aims to tame rare immune diseases
Disease control OngoingThis early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase: PHASE2, PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug hope for kids with rare Muscle-Weakening disease
Disease control OngoingThis study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and resea…
Phase: PHASE2, PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis Phase 3 study tests ritlecitinib, an oral drug, in adults with nonsegmental vitiligo, a condition causing white patches on the skin. About 1,571 participants will receive either 50 mg, 100 mg of ritlecitinib, or a placebo daily for up to 104 weeks. The goal is to see if the …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to tame Graves' disease Long-Term
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called IMVT-1402 in adults with Graves' disease, a condition where the immune system attacks the thyroid. The goal is to see if the drug can help patients stay healthy without needing other treatments. About 372 people who completed earlier studies will ta…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
MS trial withdrawn before it began: CAR T-Cell hope on hold
Disease control TerminatedThis study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New MS pill aims to outperform current treatment
Disease control OngoingThis Phase 3 study compares fenebrutinib, an experimental oral drug, to teriflunomide, an approved MS therapy, in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take eit…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New lupus shot shows promise in major trial
Disease control OngoingThis study tests a new medicine called anifrolumab, given as a shot under the skin, for adults with moderate-to-severe lupus. The goal is to see if it can better control disease activity compared to a placebo, when added to standard treatments. About 367 participants are involved…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New daily pill could rival infusion for slowing progressive MS
Disease control OngoingThis phase 3 trial compares two drugs for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens. About 985 adults with PPMS will receive either daily oral fenebrutinib or intravenous ocrelizumab (plus matching placebos) to see which better delays disab…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
CAR-T therapy targets autoimmune diseases, but trial never started
Disease control TerminatedThis study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill could slow MS relapses and disability
Disease control OngoingThis Phase 3 trial tests whether the oral drug remibrutinib works better than teriflunomide at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 1,000 adults aged 18–55 with active MS are taking part. The study is double-blind, meaning ne…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New knee implant aims to get patients moving again
Disease control OngoingThis study follows 299 people who received the Smith+Nephew Porous Total Knee System, a titanium knee replacement for severe arthritis. The goal is to see if the implant reduces pain, improves movement, and lasts at least two years without needing revision surgery. Participants a…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immune cell therapy takes on lupus in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new treatment called NKX019 for people with lupus, an autoimmune disease. NKX019 uses specially engineered immune cells to target and calm overactive B cells. The main goal is to check safety in about 6 participants, while also looking for signs tha…
Phase: PHASE1 • Sponsor: Hospital for Special Surgery, New York • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Fetal stem cells aim to tame immune chaos
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a simple pill save Insulin-Making cells in type 1 diabetes?
Disease control OngoingThis phase 2 trial tests whether the drug DFMO can protect the body's remaining insulin-producing cells in people recently diagnosed with type 1 diabetes. About 81 participants will take either DFMO or a placebo twice daily for six months. Researchers will measure insulin product…
Phase: PHASE2 • Sponsor: Emily K. Sims • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
MS patients may soon get a shot instead of an IV drip
Disease control OngoingThis phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to tame Sjogren's syndrome in major trial
Disease control OngoingThis phase 3 study tests whether ianalumab, a biologic drug, can reduce disease activity and symptoms in people with active Sjogren's syndrome. About 506 adults with a recent diagnosis (within 7.5 years) and positive anti-Ro/SSA antibodies are randomly assigned to receive ianalum…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study tests if ocrevus improves walking in MS patients
Disease control OngoingThis study looks at whether a one-year treatment with Ocrevus can improve walking and balance in people with relapsing multiple sclerosis, compared to other standard treatments. Sixty adults aged 18-65 who can walk at least 25 feet will be split into two groups. Their walking abi…
Phase: PHASE4 • Sponsor: Georgia State University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New lupus drug saphnelo tracked for Long-Term safety in 1,600+ patients
Disease control OngoingThis study is tracking the long-term safety and effectiveness of the drug Saphnelo (anifrolumab) in over 1,600 people with systemic lupus erythematosus who haven't responded well to current treatments. Researchers are monitoring for side effects like serious infections, shingles,…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Ublituximab shows promise for Long-Term MS control in large extension trial
Disease control OngoingThis study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot aims to restore skin color in vitiligo patients
Disease control OngoingThis early-stage trial tests a new drug called TEV-53408 in 38 adults with vitiligo. The main goal is to see if the drug is safe when given as a shot under the skin. Researchers will also look for early signs that it might help bring back skin color. The study lasts 84 weeks, inc…
Phase: PHASE1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug ALXN1720 aims to ease muscle weakness in myasthenia gravis
Disease control OngoingThis phase 3 trial tests whether ALXN1720 can improve daily living and muscle strength in adults with generalized myasthenia gravis who have specific antibodies. About 260 participants will receive either the drug or a placebo for 26 weeks. The study is active but no longer recru…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on lupus nephritis
Disease control ENROLLING_BY_INVITATIONThis study tests a new treatment called CHT105 for people with lupus nephritis that hasn't responded to standard therapies. CHT105 uses specially engineered immune cells from healthy donors to target and destroy the faulty immune cells causing kidney damage. Fourteen adults will …
Phase: NA • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to tame type 1 diabetes
Disease control OngoingThis study is testing whether a combination of two drugs, sotagliflozin and volagidemab, can improve blood sugar control in adults with type 1 diabetes. The 24 participants will receive both drugs or a placebo in a crossover design. The goal is to see if this approach can help ma…
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for chronic blood disorder: combo therapy aims to keep platelets stable
Disease control OngoingThis study tests whether adding ianalumab to standard eltrombopag treatment helps adults with immune thrombocytopenia (ITP) who did not get better with steroids. ITP causes low platelet counts, raising bleeding risk. The trial involves 152 participants and measures how long the t…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot could tame lupus skin flares
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-stage trial is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. KITE-363 is a type of cell therapy where a patient's own immune cells are modified in a lab to t…
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World lupus drug study launches in poland
Disease control OngoingThis study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of contr…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic aims to stabilize platelet counts in ITP patients
Disease control OngoingThis phase 3 trial tests whether adding ianalumab (a biologic drug) to standard corticosteroids helps adults with newly diagnosed immune thrombocytopenia (ITP) achieve a stable platelet response off all treatments at 12 months. About 226 participants will receive either ianalumab…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
MS treatment gets personal: could tailored infusions be just as effective?
Disease control OngoingThis study compares the standard fixed-interval dosing of ocrelizumab (every 24 weeks) with a personalized approach where infusions are given only when B cell levels rise above a certain threshold. The goal is to see if the personalized schedule is just as good at preventing rela…
Phase: PHASE4 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug sonelokimab aims to ease psoriatic arthritis pain
Disease control OngoingThis study tests a drug called sonelokimab in 960 adults with active psoriatic arthritis who have not used biologic treatments before. The goal is to see if it reduces joint pain and swelling better than a placebo. Participants receive injections over several months, and research…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
CAR-T therapy for tough arthritis cases – study pulled before start
Disease control TerminatedThis study was designed to test the safety and effectiveness of a new treatment called GC012F for people with difficult-to-treat rheumatoid arthritis. It planned to enroll adults aged 18 to 75 whose arthritis did not respond well to standard therapies. However, the study was with…
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New arthritis drug shows promise in Long-Term safety trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished an earlier study will receive the drug as a shot under the skin. Researchers will track side effects and how well the drug c…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug riliprubart tested for Long-Term control of nerve disease CIDP
Disease control ENROLLING_BY_INVITATIONThis study is a long-term extension of earlier trials testing the drug riliprubart in adults with CIDP, a condition where the immune system attacks the nerves, causing weakness and numbness. About 300 participants who completed a prior riliprubart study will continue receiving th…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Cheaper MS drug could match pricey standard in major trial
Disease control OngoingThis phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effec…
Phase: PHASE3 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for arthritis sufferers? drug tulisokibart put to the test
Disease control OngoingThis study tests a new drug called tulisokibart for people with active rheumatoid arthritis who are already taking methotrexate. About 182 participants will receive either tulisokibart or a placebo to see if the drug reduces joint pain and swelling better than a dummy treatment. …
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New antibody drug aims to halt Scleroderma's grip
Disease control OngoingThis Phase 3 trial tests whether the drug divozilimab can reduce skin thickening and protect lung function in people with systemic scleroderma, a rare autoimmune disease. About 152 adults and teens with active disease will receive either the drug or a placebo. The study is double…
Phase: PHASE3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New injectable methotrexate aims to tame rheumatoid arthritis with fewer side effects
Disease control OngoingThis phase 2 trial tests an injectable form of methotrexate called FBL-MTX for people with moderate-to-severe rheumatoid arthritis. The drug is designed to deliver methotrexate directly into the body using tiny fat bubbles, which may improve how well it works and reduce side effe…
Phase: PHASE2 • Sponsor: SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
MS drug may shield eyes from damage, new study hopes to prove
Disease control ENROLLING_BY_INVITATIONThis study looks at whether the drug ofatumumab can slow down thinning of the retina (the light-sensitive layer at the back of the eye) in people with relapsing-remitting multiple sclerosis (MS). Researchers will follow 75 adults with MS who are either starting or already taking …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for rare blistering disease: rituximab vs standard therapy
Disease control OngoingThis study compares two drugs, rituximab and cyclophosphamide, in 92 adults with severe mucous membrane pemphigoid, a rare autoimmune disease that causes painful blisters and scarring on mucous membranes. The goal is to see which treatment is safer and more effective at controlli…
Phase: PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New MS drug candidate ABP 692 faces off against ocrevus in major trial
Disease control OngoingThis study tests whether a new drug, ABP 692, works as well as the approved drug Ocrevus for people with relapsing-remitting multiple sclerosis (RRMS). About 152 adults with RRMS will receive either ABP 692 or Ocrevus to compare how the drugs move through the body and how well th…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for myasthenia gravis: experimental drug CNP-106 enters human trials
Disease control OngoingThis study tests an experimental drug called CNP-106 in 54 adults aged 18-75 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to check if the drug is safe and how it affects the immune system. Participants receive either CNP-106 or a placeb…
Phase: PHASE1, PHASE2 • Sponsor: COUR Pharmaceutical Development Company, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy may restore color in hard-to-treat vitiligo patches
Disease control OngoingThis study tests whether adding a 6-month course of methotrexate improves the results of a skin cell transplant (NCES) for adults with stable, treatment-resistant vitiligo on elbows and knees. Twenty participants will be split into two groups: one gets methotrexate before and aft…
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Daily pill may beat weekly shot for kids with MS
Disease control OngoingThis study tests whether a daily fingolimod capsule works better than a weekly interferon injection to prevent multiple sclerosis relapses in children. About 240 kids with MS will take one of the two treatments for 2 years, followed by a 5-year extension where everyone gets fingo…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New injection aims to tame lupus when standard treatments fail
Disease control OngoingThis early-stage study tests an injection called GC012F in 20 adults with refractory systemic lupus erythematosus (SLE) — a type of lupus that hasn't responded to standard treatments. The goal is to see if the therapy is safe and can reduce disease activity. Participants receive …
Phase: PHASE1, PHASE2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug DNTH103 aims to tame muscle weakness in myasthenia gravis
Disease control OngoingThis Phase 2 study tests a drug called DNTH103 (claseprubart) in 65 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either the drug or a placebo, first through an IV and then as injections under the skin every two weeks for…
Phase: PHASE2 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New modular shoulder implant aims to improve outcomes in tough revision surgeries
Disease control OngoingThis study is testing a new modular shoulder replacement system in 105 people who need complex revision surgery due to joint disease, trauma, or cancer. The device can replace part or all of the upper arm bone. Researchers are tracking how long the implant lasts and how well pati…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can schools help manage diabetes? new pilot study aims to find out
Disease control ENROLLING_BY_INVITATIONThis study tests a new program where schools, families, and doctors work together to help children manage type 1 diabetes. About 30 kids will take part to see if the program is practical and well-liked. The goal is to improve daily diabetes care at school.
Phase: NA • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can immune cells help islet transplants work better for diabetes?
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests whether adding immune cells—either the patient's own regulatory T cells or donor bone marrow cells—to a standard islet transplant can improve blood sugar control in people with brittle type 1 diabetes. About 24 adults aged 18 to 70 will receive one of…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental biologic aims to stop recurrent clots in antiphospholipid syndrome
Disease control OngoingThis early-phase trial tests an investigational biologic called EA5 in adults with antiphospholipid syndrome (APS) who have had two or more blood clots despite standard blood-thinning therapy. The study enrolls about 12 participants and gives EA5 by intravenous infusion followed …
Phase: PHASE1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis Phase 3 trial tests upadacitinib (Rinvoq), an oral immune-calming drug, in about 540 adults and teens with non-segmental vitiligo. Participants take a pill once daily for up to 160 weeks, with some receiving placebo first. The study measures how much skin color returns and t…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for rare blood disorder: drug trial targets anemia
Disease control OngoingThis phase 3 trial tests a drug called ianalumab against a placebo in 90 adults with warm autoimmune hemolytic anemia (wAIHA) who have already tried at least one treatment without success. The goal is to see if ianalumab can raise hemoglobin levels and keep them stable for at lea…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug SPY002-072 aims to tame multiple inflammatory joint diseases
Disease control OngoingThis Phase 2 study tests an experimental drug called SPY002-072 in 285 adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis. Participants receive either the drug or a placebo, and researchers measure changes in disease ac…
Phase: PHASE2 • Sponsor: Spyre Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a diabetes drug fix period problems in teens with type 1?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether dulaglutide, a drug used for type 2 diabetes, can help regulate menstrual cycles in adolescent girls with type 1 diabetes who have poor blood sugar control. Researchers will give some participants dulaglutide plus insulin, while others get only insulin…
Phase: PHASE1, PHASE2 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug batoclimab aims to ease muscle weakness in myasthenia gravis
Disease control OngoingThis phase 3 trial tests batoclimab, a drug that blocks certain antibodies, in 240 adults with generalized myasthenia gravis (gMG). The study measures if batoclimab improves daily activities and muscle strength compared to a placebo. Participants receive injections weekly or bi-w…
Phase: PHASE3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for psoriatic arthritis patients who failed Anti-TNF drugs
Disease control OngoingThis phase 3 study tests guselkumab (Tremfya) in 453 adults with active psoriatic arthritis who did not respond to or could not tolerate a prior anti-TNF drug. Participants receive either guselkumab or a placebo injection. The main goal is to see if guselkumab reduces joint swell…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug M281 aims to tame rare blood disorder
Disease control OngoingThis study tests an experimental drug called M281 (Nipocalimab) in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The trial compares M281 to a placebo to see if it can improve hemoglobin levels and reduce fatigue. About …
Phase: PHASE2, PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill could help patients with rare blood disorder
Disease control OngoingThis study tests an experimental drug called rilzabrutinib in 22 adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Participants take the drug daily for up to 24 weeks, with an option to continue longer. The main goa…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New biologic shot aims to stop psoriatic arthritis joint damage
Disease control OngoingThis phase 3 trial tested guselkumab, a biologic drug given as a shot, in over 1,000 people with active psoriatic arthritis who had not responded well to other treatments. The goal was to see if it reduces symptoms like joint pain and swelling and slows joint damage seen on X-ray…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Engineered immune cells aim to tame autoimmune attacks
Disease control TerminatedThis early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults an…
Phase: EARLY_PHASE1 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Head-to-Head: which drug works better for psoriatic arthritis?
Disease control OngoingThis study tests whether bimekizumab works better than risankizumab for adults with active psoriatic arthritis (PsA), a condition causing joint pain and skin lesions. About 684 participants will receive one of the two drugs for 16 weeks. The main goal is to see who gets at least …
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for spine pain in psoriatic arthritis: guselkumab under study
Disease control OngoingThis phase 4 trial tests whether guselkumab (TREMFYA) can reduce spine-related symptoms in people with active psoriatic arthritis who have not used biologic drugs before. About 411 participants will receive either guselkumab or a placebo as a shot under the skin. The main goal is…
Phase: PHASE4 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug nipocalimab tested in 655 Sjogren's patients in major trial
Disease control OngoingThis phase 3 trial tests whether nipocalimab can safely reduce disease activity in adults with moderate to severe Sjogren's disease. About 655 participants receive either nipocalimab or a placebo, along with standard care, for 48 weeks. The main goal is to see if the drug improve…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill could ease joint pain for psoriatic arthritis patients
Disease control OngoingThis study tests an experimental drug called JNJ-77242113 (icotrokinra) against a placebo in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The main goal is to see if the drug reduces joint swelling and tenderness after 16 weeks. Partici…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Children with Crohn's, colitis, or psoriatic arthritis get long-term safety check on stelara
Disease control OngoingThis study follows 159 children aged 2 to 17 who have already completed a prior ustekinumab study for Crohn's disease, ulcerative colitis, or psoriatic arthritis. The goal is to collect long-term safety data by monitoring side effects, lab results, and injection-site reactions. P…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New lupus drug RO7507062 enters first human safety trial
Disease control OngoingThis early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and …
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could stem cell islets end daily insulin shots?
Disease control OngoingThis early-phase trial tests VX-264, a therapy made from stem cells that produce insulin, in 7 people with long-standing type 1 diabetes. The goal is to see if it is safe and can help control blood sugar. If successful, it may reduce or replace the need for insulin injections.
Phase: PHASE1, PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Fewer needle sticks? study tests larger injector for autoimmune drug
Disease control OngoingThis study tests if a new 2mL auto-injector or pre-filled syringe delivers the same amount of the drug ianalumab into the body as the current 1mL syringe. About 155 adults with rheumatoid arthritis, Sjögren's disease, or lupus will receive the drug both ways to compare how much g…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for kids with psoriatic arthritis: drug combo under trial
Disease control OngoingThis study is testing two injectable drugs, ustekinumab and guselkumab, in 50 children with active juvenile psoriatic arthritis. The goal is to see how well the drugs work, how they move through the body, and if they are safe. Participants will receive one of the drugs and be mon…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis study tests a new drug called ianalumab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 436 participants receive either ianalumab or a placebo as a shot under the skin, once a month or once every three months, along with their u…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a cancer therapy tame severe lupus? early trial launches
Disease control OngoingThis early-phase trial is testing a new treatment called YTB323, a type of CAR T-cell therapy, in 21 adults with severe lupus that hasn't improved with standard treatments. The goal is to see if a single infusion is safe and can control the disease. Researchers will also measure …
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Smartphone system aims to simplify diabetes care for kids
Disease control OngoingThis study tests a smartphone-based system called AIDANET that works with an insulin pump and continuous glucose monitor to automatically adjust insulin for children aged 6-13 with type 1 diabetes. The goal is to see if the system is safe and works as well as usual care in keepin…
Phase: NA • Sponsor: Mark D. DeBoer, MD, MSc., MCR • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New insulin set aims to last a full week for type 1 diabetes
Disease control OngoingThis study tests a new insulin infusion set designed to last up to 7 days for people with type 1 diabetes. Twenty adults currently using a Tandem insulin pump and Dexcom CGM will try the SteadiSet at home. The goal is to see if the set can survive a full week without causing high…
Phase: NA • Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
RA drug access program offers continued treatment for prior study participants
Disease control NO_LONGER_AVAILABLEThis program provides ongoing access to certolizumab pegol (Cimzia) for adults with rheumatoid arthritis who took part in earlier open-label studies. Participants receive the standard maintenance dose of 200 mg every two weeks. The goal is to allow continued disease management or…
Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis phase 3 study tests whether adding a monthly injection of ianalumab to standard lupus treatments helps control active disease better than placebo. About 288 people aged 12 and older with systemic lupus erythematosus (SLE) are taking part. The main goal is to see if ianalumab…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a cheaper copy of ocrevus work just as well for MS?
Disease control OngoingThis phase 3 trial tests whether CYB704, a proposed biosimilar to the MS drug Ocrevus, works the same way in the body. About 183 people with relapsing multiple sclerosis will receive either CYB704 or Ocrevus. Researchers will compare drug levels, MRI scans, and side effects to se…
Phase: PHASE3 • Sponsor: Sandoz • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
MS patients on ozanimod: how long does treatment last?
Disease control OngoingThis study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting ozanimod (Zeposia®) for the first time. Researchers want to see how long patients continue the medication in everyday practice and how well it controls their disease. The study…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill could tame MS relapses
Disease control OngoingThis Phase 3 trial tests remibrutinib, an oral tablet, against teriflunomide in 1000 adults with relapsing multiple sclerosis. The goal is to see if remibrutinib better reduces yearly relapse rates and delays disability. Participants will then have the option to continue remibrut…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental CAR-T therapy targets tough autoimmune conditions
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a simple blood test guide MS treatment? new study tests ofatumumab switch
Disease control OngoingThis study looks at whether people with relapsing-remitting MS who have not had a relapse in the past year but have high levels of a nerve damage marker (NfL) in their blood would benefit from switching to the drug ofatumumab. About 136 participants will either switch to ofatumum…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New triple therapy could improve diabetes control
Disease control OngoingThis study tests whether adding two extra medications (semaglutide and dapagliflozin) to insulin helps adults with type 1 diabetes control their blood sugar better than insulin alone or with just one extra drug. The 78 participants, aged 18-70 with a BMI of 25 or higher, will be …
Phase: PHASE2, PHASE3 • Sponsor: State University of New York at Buffalo • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can these pills save Insulin-Making cells in newly diagnosed type 1 diabetes?
Disease control OngoingThis phase 2 trial tests two oral drugs, abrocitinib and ritlecitinib, in 78 people aged 12-35 who were diagnosed with type 1 diabetes within the last 100 days. The goal is to see if these JAK inhibitors can help preserve the body's ability to produce insulin, measured by a stimu…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
CAR-T therapy for autoimmune diseases: study withdrawn before starting
Disease control TerminatedThis study planned to test a new cell therapy (CD19-BCMA CAR-T) for people with connective tissue diseases like lupus and rheumatoid arthritis. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before enrolling any participants, so no…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
CAR T-Cell trial for lupus and myositis pulled before starting
Disease control TerminatedThis study aimed to test a new type of cell therapy (called CAR T-cells) in people with severe lupus or inflammatory myopathy that did not get better with standard treatments. The therapy uses donor cells to target and destroy faulty immune cells. However, the study was withdrawn…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Stem cell trial for rare bleeding disorder pulled before it began
Disease control TerminatedThis study planned to test whether infusions of mesenchymal stem cells could safely help people with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial was withdrawn before enrolling any participants, so n…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Smart insulin pumps put to the test in thousands of diabetes patients
Disease control OngoingThis study follows 1,600 people with type 1 diabetes, including young children aged 2-6, who use hybrid closed-loop insulin pumps (Medtronic, Tandem, or Omnipod). These devices automatically adjust insulin based on blood sugar readings but still require users to enter meal inform…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
MS drug ofatumumab tested for Long-Term safety in nearly 1,900 patients
Disease control OngoingThis study follows about 1,900 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Participants continue receiving ofatumumab injections every 4 weeks to monitor long-term safety, side effects, and how well the drug controls re…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Real-World study tests upadacitinib for back pain in axial spondyloarthritis
Disease control OngoingThis study looks at how well upadacitinib (RINVOQ) works for people with axial spondyloarthritis, a type of inflammatory arthritis that causes chronic back pain. About 338 adults in Germany will take the drug as prescribed by their doctor and be followed for 52 weeks. Researchers…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Lupus drug anifrolumab put to the test in Real-World study
Disease control OngoingThis study follows 551 people with lupus who are starting anifrolumab for the first time. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to see if the benefits seen in clinical trials hold up…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take on rare Muscle-Weakening disease
Disease control OngoingThis early-phase study tests a new treatment called SENL103 for people with refractory generalized myasthenia gravis, a condition that causes severe muscle weakness. The treatment uses the patient's own immune cells, modified to target and destroy harmful cells that attack the mu…
Phase: PHASE1 • Sponsor: Ting Chang, MD • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New RA pill takes on tofacitinib in Head-to-Head trial
Disease control OngoingThis phase 3 trial tests whether a new oral drug called TLL-018 works better than tofacitinib for active rheumatoid arthritis. The study includes 459 adults aged 18-65 who have not responded well to or cannot tolerate biologic treatments. Participants take either TLL-018 or tofac…
Phase: PHASE3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New implant aims to strengthen shoulder tendon repair after replacement
Disease control OngoingThis study is testing a special implant (Tapestry) that helps repair a key shoulder tendon (subscapularis) during shoulder replacement surgery. About 100 adults with shoulder arthritis or injury will be followed for 2 years to see if the tendon heals better with the implant. The …
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a lifestyle clinic help people with obesity? large trial launches
Disease control ENROLLING_BY_INVITATIONThis trial tests a 12-month lifestyle medicine program for 1000 adults with obesity and related conditions like diabetes or high blood pressure. Participants get regular visits with a dietitian and a doctor, plus optional behavioral health support. The goal is to see if the progr…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can magnetic waves tame autoimmune disease? new trial begins
Disease control ENROLLING_BY_INVITATIONThis study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…
Phase: PHASE1, PHASE2 • Sponsor: Truway Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New shot could tame lupus kidney flares
Disease control OngoingThis phase 3 trial tests whether adding ianalumab (a biologic injection) to standard therapy helps control active lupus nephritis, a serious kidney complication of lupus. About 452 adults with active lupus nephritis are receiving either ianalumab every 4 or 12 weeks or a placebo,…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could Immune-Boosting drugs treat certain psychosis?
Disease control OngoingThis phase 2 trial tests whether a combination of intravenous immunoglobulin (IVIG) and rituximab can help people with psychosis caused by antibodies attacking the brain. 70 participants with acute psychosis and specific antibodies receive either the immunotherapy or a placebo. T…
Phase: PHASE2 • Sponsor: University of Cambridge • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug shows promise for Long-Term control of back pain condition
Disease control OngoingThis study is testing the long-term safety and effectiveness of bimekizumab, a drug that reduces inflammation, in 508 adults with active axial spondyloarthritis (including ankylosing spondylitis). Participants who completed earlier trials will receive the drug for an extended per…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New MS drug copycat aims to match ocrevus in early trial
Disease control OngoingThis Phase 1 trial compares a new drug called RPH-035 to the approved MS drug Ocrevus. The study involves 180 adults with relapsing-remitting or secondary progressive multiple sclerosis who have flare-ups. Researchers are checking if RPH-035 behaves similarly in the body and has …
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising pill may halt vitiligo and bring back pigment
Disease control OngoingThis phase 2 trial tests deucravacitinib, a daily pill that targets the immune system, to see if it can stop vitiligo from spreading and help skin regain its color. About 128 adults with non-segmental vitiligo will take the drug or a placebo for 24 weeks, then some will also rece…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New lupus drug candidate cenerimod tested in chinese patients
Disease control OngoingThis phase 2 trial is testing an experimental drug called cenerimod in 15 Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE). Participants take a 4 mg tablet daily for 12 months while continuing their usual lupus medications. The study focuses on safety, ho…
Phase: PHASE2 • Sponsor: Viatris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill shows promise in quieting MS brain lesions
Disease control OngoingThis Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease acti…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New MS pill aims to slow disability in phase 3 showdown
Disease control OngoingThis study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Psoriasis drug bimekizumab: new study looks at gene changes
Disease control OngoingThis study tests the drug bimekizumab in 89 adults with moderate to severe plaque psoriasis, some of whom also have psoriatic arthritis. Researchers will measure changes in gene activity in skin samples after 48 weeks of treatment. The goal is to understand how the drug affects t…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Engineered immune cells take on rare Muscle-Weakening disease
Disease control OngoingThis early-stage study tests a new treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes severe muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells that attack the body. The …
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hip stem implant tracked for 10 years in 313 patients
Disease control OngoingThis study looks at how well the Insignia Hip Stem works and how safe it is for people needing a total hip replacement. It includes 313 adults with conditions like hip arthritis or fractures. Researchers will check implant survival and hip function for up to 10 years after surger…
Phase: NA • Sponsor: Stryker Orthopaedics • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug aims to slow lung damage in rare autoimmune disease
Disease control OngoingThis phase 2 trial tests whether tulisokibart can safely slow lung scarring in people with systemic sclerosis and interstitial lung disease. About 154 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces the yearly decline in lung fu…
Phase: PHASE2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for warm AIHA: drug trial targets blood cell destruction
Disease control OngoingThis study tests a drug called HMPL-523 (Sovleplenib) in people with warm antibody autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. About 111 adults will receive either the drug or a placebo to see if it improves hemoglobin levels and cont…
Phase: PHASE2, PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for kids with MS: drug showdown begins
Disease control OngoingThis study tests two newer multiple sclerosis drugs, ofatumumab and siponimod, against an older one, fingolimod, in 129 children aged 10 to 17. The goal is to see if the newer drugs are at least as good at preventing MS relapses. Participants take one of the three drugs for two y…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug shows promise in Late-Stage Sjogren's trial
Disease control OngoingThis phase 3 study tests whether the drug ianalumab can reduce disease activity in people with active Sjogren's syndrome. About 275 adults with the condition will receive either ianalumab or a placebo shot under the skin. The main goal is to see if the drug improves symptoms and …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New lupus drug afimetoran enters Mid-Stage trial
Disease control OngoingThis phase 2 trial tests whether the drug afimetoran can safely control active systemic lupus erythematosus (SLE) better than a placebo. About 268 participants with lupus will receive either afimetoran or a placebo for 48 weeks, with an extension period allowing placebo users to …
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Lupus drug trial hopes to tame flares with targeted antibody
Disease control OngoingThis Phase 3 study tests whether obinutuzumab, an antibody drug given by IV, can better control active lupus compared to a placebo. About 303 adults with lupus who have high disease activity and specific antibodies are taking part. All participants continue their usual lupus medi…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New MS drug frexalimab faces off against standard treatment in major trial
Disease control OngoingThis phase 3 trial compares the experimental drug frexalimab to the approved drug teriflunomide in about 1,655 adults with relapsing multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants receive either frexalimab i…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for progressive MS: drug aims to halt worsening disability
Disease control OngoingThis study tests an experimental drug called frexalimab in people with a type of progressive multiple sclerosis (MS) that is no longer causing relapses. The goal is to see if the drug can delay worsening disability compared to a placebo. About 943 adults aged 18 to 60 are taking …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug aims to ease daily struggles of myasthenia gravis patients
Disease control OngoingThis study tests a drug called inebilizumab in 238 adults with myasthenia gravis, a condition that causes muscle weakness. The main goal is to see if the drug improves patients' ability to do daily activities over 26 weeks compared to a placebo. Participants must have specific an…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a weekly shot help type 1 diabetes patients lose weight and control blood sugar?
Disease control OngoingThis phase 3 trial tests tirzepatide, a once-weekly injection, in 905 adults with type 1 diabetes who are also overweight or obese. Participants will receive either tirzepatide or a placebo for about 49 weeks. The study measures changes in blood sugar control (HbA1c) and body wei…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a simpler dosing schedule for an MS drug work just as well?
Disease control OngoingThis study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule is as safe and effective as the current approved dose. About 196 adults with relapsing MS will take part, and t…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug DR-01 tested for alopecia and vitiligo
Disease control OngoingThis early-stage study tests a new medicine called DR-01 in 81 adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. Participants are randomly assigned to…
Phase: PHASE1 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for kids with rare muscle disease: Long-Term drug safety trial begins
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a daily injection called zilucoplan in children with a rare muscle-weakening disease called generalized myasthenia gravis. It includes up to 8 children who have already completed a previous study. The goal is to see if the drug remains …
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for kids with rare muscle disease: rozanolixizumab safety trial expands
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called rozanolixizumab in children aged 2 and older with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given in 6-week treatment cycles. The main goal is to track serious side effects and see…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New tech aims to tame type 1 diabetes in kids from day one
Disease control OngoingThis study looks at whether remotely monitoring continuous glucose monitor (CGM) data can improve diabetes management in children within the first year after diagnosis. About 100 kids and teens newly diagnosed with type 1 diabetes will have their CGM data shared with their care t…
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a cancer drug tame a blood disorder?
Disease control OngoingThis phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for lupus skin sufferers: Long-Term drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 participants who were in a previous study will take cenerimod for up to 3 years, along with their usual lupus medications. Researchers will track side effects and see how well…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a weekend steroid pill stop vitiligo spreading in kids?
Disease control OngoingThis study tests whether taking dexamethasone pills twice a week for 3 months can stop active vitiligo from spreading in children aged 4 to 9. Researchers will also monitor side effects, especially on growth and bone health. The goal is to control the disease, not cure it.
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could tame lupus flares in major trial
Disease control OngoingThis phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers wil…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a cancer drug slow MS progression? new trial halted midway
Disease control TerminatedThis phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib dela…
Phase: PHASE3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gentler transplant shows promise for kids with blood diseases
Disease control OngoingThis study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer si…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
MS drug ocrelizumab tested for Long-Term safety in 1,300 patients
Disease control OngoingThis study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over many years. Participants continue their usual treatment, and researchers track side effects, disability changes, and brain scans. The goal is …
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New shot may tame stubborn lupus skin lesions
Disease control OngoingThis study tests anifrolumab, a biologic drug given as a shot, for adults with chronic or subacute lupus skin rashes that didn't get better with antimalarial drugs. About 306 participants will receive either anifrolumab or a placebo to see if the drug can reduce skin disease acti…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New program aims to keep teens with diabetes from falling through the cracks
Disease control ENROLLING_BY_INVITATIONThis study tests whether a transition coordinator can help 324 youth aged 17–18 with type 1 diabetes successfully move from pediatric to adult diabetes care. Participants get extra support before, during, and after the switch. Researchers will compare them to a group that didn't …
Phase: NA • Sponsor: University of Calgary • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo treatment for vitiligo shows promise in early trial
Disease control OngoingThis study tests whether injecting carbon dioxide gas (carboxytherapy) alongside standard narrowband UVB light therapy can improve repigmentation in people with stable vitiligo. Fifty-nine participants with symmetrical patches will receive whole-body UVB light, with carboxytherap…
Phase: PHASE4 • Sponsor: Kasr El Aini Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New shot aims to ease arthritis pain in 30-Patient trial
Disease control OngoingThis study tests an experimental injection called SHR-3045 in 30 adults with moderate to severe rheumatoid arthritis who did not get enough relief from other treatments. The goal is to see if it safely reduces joint pain and swelling. Participants are randomly assigned to receive…
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a stronger dose of an MS drug keep disability at bay?
Disease control OngoingThis study tests whether a higher dose of the drug ocrelizumab can better control relapsing multiple sclerosis (MS) and delay disability compared to the standard dose. About 864 adults with relapsing MS will receive either the higher or standard dose every 24 weeks. The main goal…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for progressive MS: ocrelizumab trial targets disability
Disease control OngoingThis study is testing the drug ocrelizumab in 927 people with progressive multiple sclerosis (MS), a form of the disease that steadily worsens. Participants receive infusions every 24 weeks for about 4 years. The main goal is to see if the drug can stop or slow disability progres…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New shoulder implant tracked in 200 patients for pain and function
Disease control OngoingThis study follows 200 adults getting a shoulder replacement with the Zimmer Trabecular Metal Reverse Shoulder System. It aims to see how long the implant lasts and how well it relieves pain and improves movement in people with conditions like arthritis, fractures, or failed prio…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a psoriasis drug help save Insulin-Making cells in type 1 diabetes?
Disease control OngoingThis phase 2 trial tests whether ixekizumab (Taltz), a drug already approved for psoriasis, can help people newly diagnosed with type 1 diabetes keep making their own insulin. The study involves 127 adults aged 18-45 who were diagnosed within the last 100 days. Participants recei…
Phase: PHASE2 • Sponsor: Göteborg University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Psoriasis cream could tame lupus skin flares
Disease control ENROLLING_BY_INVITATIONThis early study tests whether tapinarof cream, already approved for psoriasis, can improve skin lesions in people with cutaneous lupus. Ten adults with active lupus lesions will apply the cream daily for 16 weeks. Researchers will measure changes in skin activity and study immun…
Phase: EARLY_PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can a pill keep vitiligo at bay? new study aims to find out
Disease control OngoingThis study tests a daily pill called ritlecitinib in adults and teens with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color regained in a previous study, or if stopping it leads to colo…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Artificial pancreas implant shows promise for diabetes control
Disease control OngoingThis early-stage study tested a device called Beta-Air, which contains insulin-producing cells, in 4 adults with long-standing type 1 diabetes. The main goal was to see if the implant is safe. Researchers also checked if it could help control blood sugar and reduce dangerous low …
Phase: PHASE1, PHASE2 • Sponsor: Uppsala University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Sjögren's drug ianalumab tested for Long-Term safety in 600-Patient trial
Disease control OngoingThis phase 3 study tests the long-term safety of ianalumab in 612 people with Sjögren's syndrome who already completed a year of treatment in earlier trials. Participants receive ianalumab or placebo injections for up to several more years. The goal is to see if the drug remains …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a pill tame lupus? large trial tests upadacitinib
Disease control OngoingThis phase 3 study tests whether upadacitinib (RINVOQ), a drug already used for arthritis, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year. Researchers will measure how well it reduces disease acti…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could stem cells help kids with New-Onset diabetes?
Disease control OngoingThis study tests a single infusion of stem cells from donated umbilical cord tissue (Wharton's jelly) in 66 children and teens aged 7–21 who were diagnosed with type 1 diabetes within the last 6 months. The goal is to see if the treatment is safe and can help the body produce mor…
Phase: PHASE1, PHASE2 • Sponsor: Uppsala University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New study tests whether No-Cement knee implants outperform traditional ones
Disease control OngoingThis study compares two types of total knee replacement systems: one that uses cement to hold the implant in place and one that does not. Researchers will track 300 patients with knee pain from arthritis or deformity over 5 years to see which implant leads to better pain relief, …
Phase: NA • Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hip implant under study for Long-Term success
Disease control OngoingThis study is checking how well a new hip replacement part (the HYPE stem) works and lasts over 10 years. About 180 people with hip disease from arthritis or injury will get the implant. Doctors will use X-rays and surveys to see if the implant stays firmly in place and helps red…
Sponsor: Societe dEtude, de Recherche et de Fabrication • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hip replacement device study pulled before it started
Disease control TerminatedThis study planned to test a new hip replacement device (the HYPE stem) in people with hip arthritis or other hip damage. The goal was to see how well the device works and if it is safe. However, the study was withdrawn before any participants were enrolled, so no results are ava…
Sponsor: Societe dEtude, de Recherche et de Fabrication • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a common supplement ease lupus?
Disease control OngoingThis study tests whether N-acetylcysteine (NAC), an antioxidant supplement, can help people with systemic lupus erythematosus (SLE). About 290 participants will first take NAC for 3 months to find a tolerable dose, then be randomly assigned to continue NAC or switch to a placebo …
Phase: PHASE2 • Sponsor: State University of New York - Upstate Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug tested for Long-Term safety in kids with rare muscle disease
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of efgartigimod in children with generalized myasthenia gravis, a disease that causes muscle weakness. The 12 participants are kids who already took part in earlier studies of this drug. They will continue to receive efgartigimod either th…
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot could help when arthritis drugs fail
Disease control OngoingThis study tests a new drug called IMVT-1402 in 120 adults with active, difficult-to-treat rheumatoid arthritis. Participants receive weekly injections of either the drug or a placebo. The goal is to see if the drug helps maintain symptom improvement over 28 weeks.
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could stem cells help newly diagnosed type 1 diabetes patients?
Disease control OngoingThis early-stage trial tests whether a single infusion of umbilical cord stem cells can safely preserve insulin production in adults newly diagnosed with type 1 diabetes. Sixty participants will receive either the stem cells or a placebo. The main goal is to see if the treatment …
Phase: PHASE1 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cell therapy for MS enters human safety testing
Disease control OngoingThis early-stage study tests an experimental cell therapy called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to see if it is safe and how the body handles it. Researchers will also measure how long the cells last and how they affect the immune system.
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Shoulder device under 10-Year watch
Disease control OngoingThis study follows 194 people who received the Comprehensive Nano shoulder device to replace their shoulder joint due to arthritis, bone death, or deformity. Researchers will track how long the implant lasts and how well patients can use their shoulder over 10 years. The goal is …
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for lung scarring: phase 3 trial underway
Disease control OngoingThis study tests an experimental drug, BMS-986278, in about 1057 adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. Participants receive either the drug or a placebo to see if it can slow lung function decline and is safe. The trial is …
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New knee implant tested for better mobility and less pain
Disease control ENROLLING_BY_INVITATIONThis study is testing a new knee implant called the Persona SoluTion PPS femur in 200 adults who need total knee replacement. The goal is to see if it safely improves knee function and reduces pain over two years. Participants will have their knee health measured before surgery a…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a custom vaccine retrain the immune system in type 1 diabetes?
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for type 1 diabetes. The treatment uses a vaccine made from the patient's own immune cells and a piece of insulin-producing cell protein. The goal is to teach the immune system to stop attacking the pancreas, potentially pr…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New injection every 8 weeks shows promise for thyroid eye disease
Disease control OngoingThis study tests a drug called TOUR006 in 79 people with active thyroid eye disease, a condition that causes eye bulging and inflammation. Participants receive either a low dose, high dose, or placebo injection every 8 weeks. The main goal is to see if the drug can reduce eye bul…
Phase: PHASE2 • Sponsor: Tourmaline Bio, Inc., a Novartis Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New daily pill aims to tame psoriatic arthritis without injections
Disease control OngoingThis phase 3 study tests whether deucravacitinib, a daily pill, can reduce joint pain and swelling in people with active psoriatic arthritis who have never used biologic drugs. About 670 participants will receive either the drug or a placebo for 16 weeks, with a long-term extensi…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising drug trial for kids with rare Muscle-Weakening disease
Disease control OngoingThis study tests a drug called ravulizumab in 12 children aged 6 to 18 with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The goal is to see how the drug works in the body and if it helps control symptoms. Participants receive the drug through an I…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for vitiligo: which cream boosts light therapy best?
Disease control OngoingThis study tests whether adding a tacrolimus or tyrosine cream to standard UVB light therapy helps restore skin color in adults with vitiligo. About 67 participants will receive both creams on different patches and be followed for 3 months. The goal is to see which combination le…
Phase: NA • Sponsor: Minia University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug CND261 tested for rheumatoid arthritis relief
Disease control OngoingThis early-stage study tests a new drug, CND261, in 47 adults with moderate to severe rheumatoid arthritis who haven't responded well to other treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that it might…
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New shot aims to keep insulin flowing in type 1 diabetes
Disease control OngoingThis study tests a drug called Diamyd in people aged 12 to 29 who were recently diagnosed with type 1 diabetes and have a specific genetic type (HLA DR3-DQ2). The goal is to see if Diamyd can help the body keep making its own insulin, which could improve blood sugar control and r…
Phase: PHASE3 • Sponsor: Diamyd Medical AB • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug hopes to tame hardening skin disease
Disease control TerminatedThis study tests a new drug called CM-101 for people with systemic sclerosis, a disease that causes skin hardening and organ damage. About 45 adults will receive either the drug or a placebo to check safety and how well the body tolerates it. The goal is to see if CM-101 can redu…
Phase: PHASE2 • Sponsor: ChemomAb Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New lupus drug enpatoran tested for long-term safety
Disease control OngoingThis study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…
Phase: PHASE2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Walking more could protect hearts of type 1 diabetes patients
Disease control OngoingThis study looks at whether doing light aerobic exercise five days a week can improve heart rate variability—a sign of heart health—in adults with type 1 diabetes. Over one year, 35 participants were split into two groups: one exercised regularly, the other less often. Researcher…
Phase: NA • Sponsor: University of Banja Luka • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a tiny neck implant calm rheumatoid arthritis without pills?
Disease control OngoingThis study tests a small device implanted on the vagus nerve in the neck to treat moderate to severe rheumatoid arthritis. About 243 adults who did not get enough relief from standard drugs will receive either active or inactive stimulation for 12 weeks, then all will receive act…
Phase: PHASE3 • Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New shot could tame Sjögren's symptoms in major trial
Disease control OngoingThis phase 3 trial tests whether efgartigimod, given as a shot under the skin, can reduce disease activity in adults with moderate-to-severe primary Sjögren's disease. About 631 participants will receive either the drug or a placebo for 48 weeks, with an option to continue treatm…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThis study tests an experimental drug called ifetroban in 34 adults with a severe form of scleroderma (diffuse cutaneous systemic sclerosis) or scleroderma-related lung disease (pulmonary arterial hypertension). The main goal is to see if the drug is safe and whether it can impro…
Phase: PHASE2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Real-world MS drug study tracks relapse reduction in italian patients
Disease control OngoingThis study looks at how well ofatumumab (Kesimpta®) works for people with relapsing-remitting multiple sclerosis (RRMS) in real-life settings across Italy. About 379 adults already prescribed the drug will be followed for 12 months to measure relapse rates and thinking speed. The…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Old TB vaccine shows promise for type 1 diabetes control
Disease control OngoingThis study tests whether repeated doses of the BCG vaccine (originally for tuberculosis) can help adults with long-standing type 1 diabetes lower their blood sugar levels. About 150 participants receive either BCG or a placebo over 5 years, with follow-up for 10 years. The goal i…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for ITP patients: experimental drug aims to boost platelets
Disease control OngoingThis phase 2 trial tests an experimental drug called ianalumab in 41 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants have already tried steroids and another standard treatment. The study mea…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New app and coach aim to close diabetes tech gap for black children
Disease control OngoingThis study is testing whether a smartphone app called Glucosano, combined with help from a community health worker, can make it easier for Black children and young adults with type 1 diabetes to use advanced diabetes technologies like automated insulin delivery systems. The goal …
Phase: NA • Sponsor: Sarah MacLeish • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo shows promise for rare blood disorder
Disease control OngoingThis study tests whether adding eltrombopag to standard immunosuppressive therapy can improve blood cell counts in people with untreated severe aplastic anemia. Participants receive horse-ATG and cyclosporine plus eltrombopag for up to 6 months. The goal is to see if this combina…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Dietary intervention aims to tame weight regain in Graves' patients
Disease control OngoingThis study tests whether a personalized low-calorie Mediterranean-style diet, combined with lifestyle coaching, can prevent people newly diagnosed with Graves' disease from regaining too much weight after their thyroid levels normalize. Fifty-four adults will be randomly assigned…
Phase: NA • Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
App aims to boost blood sugar control in type 1 diabetes
Disease control OngoingThis study tests whether a smartphone app called Hedia Diabetes Assistant can help adults with type 1 diabetes keep their blood sugar in a healthy range more often. About 154 people with poorly controlled diabetes will either use the app plus their usual care or just usual care f…
Phase: NA • Sponsor: Hedia ApS • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Can a diabetes drug protect blood vessels in type 1 diabetes?
Disease control TerminatedThis phase 2 trial tests whether dulaglutide, a drug used for type 2 diabetes, can improve small blood vessel function in adults with type 1 diabetes. The study involves 47 participants aged 18-40 with long-standing type 1 diabetes. Researchers measure blood flow and insulin sens…
Phase: PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Paramedics at your door: new program fights dangerous low blood sugar
Disease control TerminatedThis study tests a program where community paramedics visit adults with diabetes who have had severe low blood sugar (hypoglycemia). The goal is to help them better manage their diabetes, prevent future emergencies, and improve their quality of life. About 150 participants from s…
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New lupus pill shows promise in Mid-Stage trial
Disease control OngoingThis Phase 2 study tests an experimental oral drug called ESK-001 in 408 adults with active systemic lupus erythematosus (SLE). Participants receive either ESK-001 or a placebo for 48 weeks to see if the drug can reduce disease activity. The goal is to find a new treatment option…
Phase: PHASE2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Fishy friends: pet care may boost diabetes control in teens
Disease control ENROLLING_BY_INVITATIONThis study tests whether adding a pet fish to a teen's diabetes routine can improve blood sugar control and monitoring. Sixty early adolescents aged 10-13 with type 1 diabetes will either follow a structured fish care plan linked to their diabetes tasks or receive collaborative c…
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Stem cell shot aims to tame multiple sclerosis
Disease control OngoingThis early-stage trial tests a single intravenous dose of IMS001, a stem cell product made from human embryonic cells, in 30 adults with multiple sclerosis who have not responded well to standard treatments. The main goal is to see if the treatment is safe and tolerable, while al…
Phase: PHASE1 • Sponsor: ImStem Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New glucose monitor aims to prevent dangerous low blood sugar in kids
Disease control OngoingThis study is testing the safety of the FreeStyle Libre 2, a device that continuously checks blood sugar levels, in 550 children and young adults aged 4 to 30 with type 1 or type 2 diabetes. The goal is to see if using this monitor reduces severe low blood sugar events that need …
Sponsor: Abbott Diabetes Care • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Islet transplant trial aims to free type 1 patients from severe lows
Disease control OngoingThis phase 3 study tests whether transplanting insulin-making cells (islets) from donors can improve blood sugar control in people with type 1 diabetes who still have dangerous low blood sugar episodes despite intensive insulin therapy. About 21 participants receive the transplan…
Phase: PHASE3 • Sponsor: CellTrans Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Withdrawn study: could hydroxychloroquine help High-Risk pregnancies?
Disease control TerminatedThis study was designed to see if adding hydroxychloroquine to standard treatment (aspirin and heparin) could help women with antiphospholipid syndrome have a healthy full-term pregnancy. It planned to enroll pregnant women before 14 weeks of gestation. However, the trial was wit…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug aims to quiet MS brain lesions
Disease control OngoingThis Phase 2 trial tests an experimental drug called LY3541860 against a placebo in 63 adults with relapsing multiple sclerosis. The goal is to see if the drug can slow the appearance of new brain lesions seen on MRI scans. The study lasts about 9 months, with an additional 6 mon…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Smart pump trial aims to tame tough diabetes cases
Disease control OngoingThis study tests whether a hybrid closed-loop insulin pump system (mylife CamAPS FX) can improve blood sugar control and quality of life in 30 adults with type 1 diabetes who have chronically high blood sugar and psychological challenges. Participants either start the pump immedi…
Phase: NA • Sponsor: Jerzy Hohendorff • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a cancer drug fix blood cell problems after transplant?
Disease control OngoingThis phase 2 trial tests whether isatuximab can help people whose blood cell counts stay low after a stem cell transplant for blood cancer. The study enrolls 12 adults whose disease is in remission but who have developed immune-related blood cell deficiencies. Participants receiv…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo shot aims to tame type 1 diabetes
Disease control OngoingThis early-stage trial tests a new weekly injection called NNC0194-0499, alone or with another drug (semaglutide), in 96 adults with type 1 diabetes. The goal is to see if it improves blood sugar levels compared to placebo. All participants continue their usual insulin. The study…
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activi…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control ENROLLING_BY_INVITATIONThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New toolkit aims to keep diabetes patients safe after hospital discharge
Disease control OngoingThis study tests a special toolkit designed to help people with type 2 diabetes who are starting insulin for the first time when they leave the hospital. About 120 English-speaking adults will be randomly assigned to receive the toolkit or usual care. The goal is to see if the to…
Phase: NA • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New shoulder replacement system tracked in global study
Disease control ENROLLING_BY_INVITATIONThis study is following 110 people who received a Tornier HRS shoulder replacement to see how well it improves pain and function. Participants have conditions like arthritis, fractures, or rotator cuff tears. The goal is to collect long-term safety and performance data for regula…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise for vitiligo in major trial
Disease control OngoingThis study tests a daily pill called povorcitinib to see if it can safely bring back skin color in people with nonsegmental vitiligo, a condition where white patches appear on the skin. About 450 adults will receive either the drug or a placebo for 52 weeks. The main goal is to m…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could a stronger dose of ocrevus slow MS disability better?
Disease control OngoingThis Phase 3 trial is testing whether a higher dose of the drug ocrelizumab (Ocrevus) can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS are receiving either the standard approved dose or a higher dose b…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
MS drug holiday for Over-50s: safe or risky?
Disease control OngoingThis study looks at whether people over 50 with a stable, inactive form of secondary progressive multiple sclerosis can stop taking their disease-modifying drugs without getting worse. Researchers will track 250 participants for 2 years to see if stopping treatment leads to more …
Phase: PHASE3 • Sponsor: Rennes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill could tame Sjögren's syndrome
Disease control OngoingThis phase 3 trial tests deucravacitinib, an anti-inflammatory pill, in 774 adults with active Sjögren's syndrome. Participants receive either the drug or a placebo for 52 weeks. The goal is to see if the drug reduces disease activity and improves symptoms like dryness and fatigu…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Multiple sclerosis CAR-T trial pulled before it even started
Disease control TerminatedThis early-stage study aimed to test a single infusion of GC012F CAR-T cells in people with multiple sclerosis. The goal was to check safety and see if the treatment could control the disease. However, the trial was withdrawn before enrolling any participants, so no data was coll…
Phase: EARLY_PHASE1 • Sponsor: Huashan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New study checks safety of injectable remsima for arthritis and psoriasis
Disease control OngoingThis study is observing about 881 people with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis who are taking Remsima (a biologic drug) either as a shot under the skin or through an IV. The goal is to track any serious side effects over time. Resear…
Sponsor: Celltrion • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could Lab-Grown cells free diabetics from insulin shots?
Disease control ENROLLING_BY_INVITATIONThis early study tests lab-grown pancreatic islet cells (CRG-002) in 10 adults with type 1 or pancreatogenic diabetes who have severe low blood sugar episodes. The cells are infused into the liver or placed under the belly skin. The goal is to see if they are safe and can help th…
Phase: EARLY_PHASE1 • Sponsor: Celregen Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New lupus drug candidate enters Mid-Stage trial
Disease control OngoingThis Phase 2 trial tests whether the experimental drug SAR441344 can safely control disease activity in people with active systemic lupus erythematosus (SLE). About 109 adults aged 18–70 will receive either the drug or a placebo for 24 weeks. The main goal is to see if more peopl…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on lupus in tiny trial
Disease control OngoingThis Phase 2 trial is testing a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE). Descartes-08 uses a patient's own immune cells, modified to target a protein called BCMA, to try to control the disease. Only 6 participants with active lupus des…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shoulder implant tracked for 10 years in 73 patients
Disease control OngoingThis study follows 73 people who received a shoulder replacement using the Anatomical Shoulder Domelock System. The goal is to see how well the device works and how safe it is over 10 years. Participants have conditions like arthritis or avascular necrosis and have not improved w…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New ankle implant tracked for 10 years in arthritis patients
Disease control OngoingThis study follows 200 adults with ankle arthritis who received the INFINITY ankle replacement. Researchers will check how long the implant lasts and monitor for any problems like loosening or cysts over 10 years. The goal is to see if this device works as well as other similar i…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis phase 3 trial tests an oral drug called povorcitinib in about 467 adults with nonsegmental vitiligo, a condition causing white patches on the skin. Participants take the drug or a placebo daily for 52 weeks to see if it safely improves skin color on the face and body. The go…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a new immune system fix T-Cell diseases? trial tests donor transplants
Disease control OngoingThis study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, followed by donor stem cells. The goal is to see if the new immune system can co…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for kids with arthritis: drug trial shows promise
Disease control OngoingThis study tests whether the drug ixekizumab is safe and effective for children with certain types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). About 101 children aged 2 to 17 years will receive either ixekizumab or the standard drug adal…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a cancer drug ease diabetes in kids with rare fat disease?
Disease control OngoingThis study tests whether cyclophosphamide, a drug that calms the immune system, can reduce insulin needs in people with a rare condition that causes fat loss (lipodystrophy) and type 1 diabetes. Ten participants will receive the treatment, and researchers will measure how much in…
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Hip implants under the microscope: 8-Year Follow-Up study launched
Disease control ENROLLING_BY_INVITATIONThis study is checking the long-term safety and performance of two hip implant devices (RingLoc Bipolar Acetabular Cup and Endo II Femoral Head) used in hip replacement surgery. Researchers will follow 116 patients who had their surgery at least eight years ago, tracking complica…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New shot could tame Sjögren's Flare-Ups
Disease control OngoingThis Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Double-Drug attack on rheumatoid arthritis shows promise in new trial
Disease control OngoingThis Phase III trial tests whether combining baricitinib with an anti-TNF drug (adalimumab or etanercept) works better than baricitinib alone for people with rheumatoid arthritis who haven't responded to prior treatments. The study involves 160 adults aged 18-65 with active disea…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a probiotic protect Insulin-Making cells in newly diagnosed type 1 diabetes?
Disease control OngoingThis phase 2 trial tests whether a probiotic called Lactiplantibacillus plantarum (Lp299v) can reduce inflammation and help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. The study includes 60 participants aged 3 to 45 who were diagnos…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for Hard-to-Treat seizures: cenobamate under study
Disease control ENROLLING_BY_INVITATIONThis study looks at whether the drug cenobamate can help reduce seizures in adults with autoimmune epilepsy, a condition where the immune system attacks the brain. Researchers will track 30 participants for 24 weeks to see if seizure frequency drops by at least half. The goal is …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a common supplement slow MS brain damage? new trial seeks answers.
Disease control OngoingThis study tests whether N-acetyl cysteine (NAC), a supplement, can protect the brain in people with progressive multiple sclerosis (MS). About 98 adults with primary or secondary progressive MS will receive either NAC or a placebo for 15 months. Researchers will measure brain sh…
Phase: PHASE2 • Sponsor: Emmanuelle Waubant, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a tiny device free people with type 1 diabetes from daily shots?
Disease control OngoingThis early-stage trial tests a small device placed under the skin that contains insulin-producing cells. The goal is to see if it is safe and tolerable for people with type 1 diabetes who already receive standard islet transplants. Only 10 participants are enrolled, and the main …
Phase: PHASE1 • Sponsor: Encellin • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
MS patients may benefit from switching Immune-Suppressing drugs
Disease control OngoingThis study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can help restore immune function and reduce infections in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch imp…
Sponsor: Ente Ospedaliero Cantonale, Bellinzona • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aims to save Insulin-Making cells in type 1 diabetes
Disease control OngoingThis study tests brivekimig, a drug that targets inflammation, to see if it can help people with newly diagnosed type 1 diabetes keep making their own insulin. About 84 adults and adolescents will receive either brivekimig or a placebo for 52 weeks. The main goal is to measure in…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
GBS drug trial pulled before it even started
Disease control TerminatedThis study aimed to test the safety and effectiveness of efgartigimod in people with Guillain-Barre syndrome (GBS), a rare nerve disorder causing weakness. Participants would have received the drug alongside standard care and undergone blood tests and surveys. However, the trial …
Phase: PHASE2 • Sponsor: Chafic Karam • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can your own stem cells repair MS nerve damage? new trial aims to find out
Disease control OngoingThis early-phase trial tests whether a patient's own bone marrow stem cells, injected into the spinal fluid, can repair nerve damage caused by progressive multiple sclerosis. The study involves 18 adults with secondary or primary progressive MS. Researchers will measure changes i…
Phase: PHASE1, PHASE2 • Sponsor: Haukeland University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New diabetes drink shows promise in nutrition study
Disease control OngoingThis study compares a new diabetes-specific nutritional formula to an existing one in 103 adults with type 1 diabetes, type 2 diabetes, or prediabetes who are at risk for malnutrition. The goal is to see if the new formula is as good as the current one at improving nutrition, mea…
Phase: NA • Sponsor: Abbott Nutrition • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise for psoriatic arthritis in major trial
Disease control OngoingThis phase 3 study tests whether tildrakizumab, an injected drug, can reduce joint pain and swelling in people with active psoriatic arthritis who have not used anti-TNF treatments before. About 296 adults will receive either the drug or a placebo. The main goal is to see if at l…
Phase: PHASE3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New knee implant under Long-Term review
Disease control OngoingThis study follows 737 people who received a Persona knee implant to see how long it lasts and how well it works. Participants are adults aged 18-75 with severe knee pain from conditions like arthritis or bone damage. The goal is to track implant survival and knee function over t…
Phase: NA • Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New lupus injection enters first human tests
Disease control OngoingThis early-stage trial tests a new drug called SG301, given as an injection under the skin every two weeks, for systemic lupus erythematosus (SLE). The study first gives a single dose to healthy volunteers to check safety, then gives multiple doses to people with lupus. The main …
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for psoriatic arthritis: tildrakizumab shows promise in Long-Term trial
Disease control OngoingThis phase 3 study is testing the long-term safety and effectiveness of tildrakizumab, a biologic drug given as an injection, in people with psoriatic arthritis. Researchers are tracking side effects and how well the drug reduces joint pain, swelling, and other symptoms over time…
Phase: PHASE3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Promising autoimmune therapy trial pulled before it even started
Disease control TerminatedThis study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug hope for rare blood disorder that causes anemia in cold weather
Disease control OngoingThis phase 2 trial tests the drug zanubrutinib (Brukinsa) in 25 people with primary cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures, causing anemia and poor circulation. The study aims to see if the drug can reduce an…
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
CAR-T cells take on rheumatoid arthritis in Head-to-Head trial
Disease control OngoingThis phase I/II trial compares a single dose of CAR-T cell therapy (KYV101) to two doses of rituximab in 13 people with active, treatment-resistant rheumatoid arthritis. The main goals are to check safety and see if the CAR-T treatment can turn off certain immune markers linked t…
Phase: PHASE1, PHASE2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can a healthy diet prolong the 'Honeymoon Phase' in kids with type 1 diabetes?
Disease control OngoingThis pilot study is testing whether giving children (ages 6-17) newly diagnosed with stage 3 type 1 diabetes free weekly healthy foods and intensive nutrition counseling can help preserve their remaining insulin production. The study will enroll 20 children and measure how feasib…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Blood clot drug trial for rare autoimmune disease pulled before start
Disease control TerminatedThis study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS). APS is an autoimmune disease that increases clot risk. The trial was withdrawn before enrolling any participants, so no re…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a smart monitor improve blood sugar control for dialysis patients?
Disease control OngoingThis study tests whether using a continuous glucose monitor (CGM) helps dialysis patients with type 1 or type 2 diabetes control their blood sugar better than standard finger-prick tests. 96 participants will be split into three groups: standard care, intermittent CGM use, or con…
Phase: NA • Sponsor: Bo Feldt-Rasmussen • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Hope for teens with down syndrome regression disorder: old drugs, new purpose
Disease control OngoingThis Phase 2 trial tests three commonly used drugs—lorazepam, IVIG, and tofacitinib—in 66 people aged 8 to 30 with Down Syndrome Regression Disorder (DSRD). DSRD causes sudden severe symptoms like loss of speech, movement, and daily living skills. The study aims to see if these d…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Vitamin e in knee implants: a Long-Term showdown
Disease control OngoingThis study looks at two kinds of plastic used in total knee replacement surgery: one with vitamin E and one without. The goal is to see which one lasts longer, causes less wear, and helps patients move better. About 605 adults with knee arthritis or similar problems took part, an…
Sponsor: Aesculap AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a stem cell transplant stop the immune system from attacking the brain?
Disease control OngoingThis phase 2 trial tests whether high-dose chemotherapy followed by a stem cell transplant can stop the immune system from attacking the nervous system in people with autoimmune neurologic diseases like multiple sclerosis and stiff person syndrome. The treatment aims to weaken th…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New implantable 'Cell Pouch' could free diabetics from insulin shots
Disease control OngoingThis study tests a device called the Cell Pouch, which is implanted in the abdomen to create a natural home for donor insulin-producing cells. The goal is to help people with type 1 diabetes who have dangerous low blood sugar episodes. Seventeen participants will receive the impl…
Phase: PHASE1, PHASE2 • Sponsor: Sernova Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New MS pill aims to slash relapses in major trial
Disease control OngoingThis phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…
Phase: PHASE3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill aims to stop MS relapses in its tracks
Disease control OngoingThis Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …
Phase: PHASE3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for progressive MS: ocrelizumab trial targets disability
Disease control OngoingThis phase 3 trial tests whether ocrelizumab (Ocrevus) can slow disability progression in adults with primary progressive multiple sclerosis (PPMS). Over 1,000 participants receive either the drug or a placebo. The main goal is to see if the drug delays worsening of hand function…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New shot could help celiac patients who still suffer despite strict diet
Disease control OngoingThis study tests a drug called amlitelimab in adults with celiac disease who still have symptoms even after following a gluten-free diet for at least a year. About 229 participants will receive either the drug or a placebo as a shot under the skin for up to 28 weeks. The goal is …
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Hip replacement stem under review: 5-Year safety and performance study
Disease control OngoingThis study looks at the safety and performance of a cemented hip stem (TrendHip®) in 119 people who had hip replacement surgery. It tracks pain, function, and quality of life for up to 5 years after surgery. The goal is to confirm the device works well in everyday use.
Phase: NA • Sponsor: Aesculap AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New LabPatch could replace finger pricks for diabetes patients
Diagnosis OngoingThis study tests a new device called LabPatch that measures blood sugar from fluid just under the skin. About 60 adults with type 1 or type 2 diabetes who use insulin will wear the patch for 6 hours. Researchers will compare its readings to standard lab tests and two commercial g…
Sponsor: Joslin Diabetes Center • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New blood test could spot type 1 diabetes before symptoms strike
Diagnosis OngoingThis study looks for tiny particles in the blood, called exosomes, that might signal the start of type 1 diabetes. Researchers will compare children recently diagnosed with type 1 diabetes to healthy children, all aged 12 to 18. The goal is to find a better way to catch the disea…
Sponsor: AdventHealth Translational Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
New Mail-In kit could make diabetes monitoring easier
Diagnosis OngoingThis study tests a home collection kit for people with diabetes to measure their HbA1c, a key blood sugar marker. 63 adults with Type 1 or Type 2 diabetes will use the kit and mail a dried blood spot to the lab. The goal is to see if the kit is accurate and easy to use, which cou…
Sponsor: University Hospitals of North Midlands NHS Trust • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
New program aims to cut heart risks in psoriasis patients
Prevention OngoingThis study tests whether a dedicated care coordinator can help people with psoriasis or psoriatic arthritis reduce their risk of heart disease. About 520 adults aged 40-75 who do not already take cholesterol medication will receive support to manage risk factors like high cholest…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Could a simple injection stop type 1 diabetes before it starts?
Prevention OngoingThis phase II trial tests a drug called Diamyd, given as injections into lymph nodes, to see if it is safe and can prevent type 1 diabetes in children aged 8 to 17 who are at high risk. Only 5 participants are enrolled, and the study focuses on safety and whether the drug can sto…
Phase: PHASE2 • Sponsor: Diamyd Medical AB • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Low-gluten diet in toddlers may cut celiac risk, study finds
Prevention OngoingThis study looks at whether giving children with a genetic risk for celiac disease a low-gluten diet (less than 3 grams per day) during their first three years of life can lower their chance of developing the disease by age 7. About 1,100 children from Sweden are taking part. The…
Phase: NA • Sponsor: Lund University • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
New study tests physical therapy to boost exercise in MS patients
Symptom relief OngoingThis study tests whether a 24-week physical therapy program can help people with multiple sclerosis become more physically active. Forty participants will receive tailored exercise support and education. The goal is to see if this approach is feasible and helps manage MS symptoms…
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New app aims to tackle diabetes stress in School-Age children
Symptom relief OngoingThis study tests a mobile health program called R2D2 designed to reduce diabetes distress in children aged 8-12 with type 1 diabetes and their parents. The program uses cognitive behavioral therapy, mindfulness, and behavioral strategies to help families cope. Researchers will me…
Phase: NA • Sponsor: Nemours Children's Clinic • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Spinal zaps at home could restore hand control in MS
Symptom relief ENROLLING_BY_INVITATIONThis pilot study explores whether non-invasive electrical stimulation of the spinal cord, combined with hand and arm exercises, can improve upper limb function in people with multiple sclerosis. Participants use a home device with help from a partner over 8 weeks. The study focus…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New app aims to ease depression and pain in ankylosing spondylitis patients
Symptom relief OngoingThis pilot study tests a WeChat-based program that provides daily mental health check-ins and tailored coping strategies for people with ankylosing spondylitis who also have mild-to-moderate depression or anxiety. Thirty-six adults will be split into two groups: one receives the …
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Peer support may help MS patients stay on track with meds
Symptom relief OngoingThis pilot study tests whether one-on-one peer support sessions can help people with relapsing-remitting multiple sclerosis stay on their prescribed medications. Sixty adults will be randomly assigned to receive either standard care or three hour-long sessions with a trained peer…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Can online therapy help scleroderma patients manage daily life?
Symptom relief OngoingThis pilot study tests whether a personalized online occupational therapy program is feasible and helpful for adults with scleroderma. Twenty-four participants in Spain will either receive eight online therapy sessions over four weeks plus usual care, or usual care alone. The stu…
Phase: NA • Sponsor: Universidad de Zaragoza • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Talking therapy aims to ease the emotional burden of type 1 diabetes
Symptom relief OngoingThis study tests whether cognitive behavioral therapy (a type of talking therapy) delivered online, along with a continuous glucose monitor, can reduce diabetes-related distress in adults with type 1 diabetes. About 93 adults aged 18-64 will be randomly assigned to receive either…
Phase: NA • Sponsor: Albert Einstein College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Fasting diet shows promise for psoriasis relief
Symptom relief OngoingThis pilot study explores whether a 7-day fast followed by 11 weeks of a plant-based diet can reduce skin and joint symptoms in people with psoriasis and psoriatic arthritis. Researchers will also look at changes in gut bacteria and overall quality of life. The study involves 30 …
Phase: NA • Sponsor: Charite University, Berlin, Germany • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Online workouts may boost brain speed in MS patients
Symptom relief OngoingThis study tests whether a guided internet-based physical activity program can improve cognitive processing speed in people with multiple sclerosis. 280 participants who have mild walking difficulties and slowed thinking will be randomly assigned to either the exercise program or…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Nerve-Zapping gadget could tame MS symptoms at home
Symptom relief OngoingThis study tests if a gentle, non-invasive nerve stimulation device can help manage symptoms of multiple sclerosis (MS), like fatigue and pain. Thirty women with MS will use the device at home for a few weeks. The goal is to see if it's practical and if it reduces symptom burden,…
Phase: NA • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Could a Low-Dose ketamine infusion beat MS fatigue?
Symptom relief OngoingThis phase 2 trial tests whether a single low-dose ketamine infusion can reduce fatigue in people with multiple sclerosis. About 110 adults with MS-related fatigue will receive either ketamine or a mild sedative (midazolam) as a placebo. The study measures changes in fatigue scor…
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
New drug aims to ease daily misery of rare mast cell disease
Symptom relief OngoingThis phase 2 study tests whether the experimental drug bezuclastinib can reduce symptoms like itching, flushing, and fatigue in people with nonadvanced systemic mastocytosis, a rare condition where too many mast cells cause chronic discomfort. About 237 adults whose symptoms are …
Phase: PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Turmeric and blue light may heal blisters in rare skin disease
Symptom relief OngoingThis study tests whether a gel made from curcumin (the active part of turmeric) combined with blue LED light can heal painful mouth blisters in people with epidermolysis bullosa, a rare condition that makes skin and mucous membranes extremely fragile. Twenty participants will rec…
Phase: PHASE4 • Sponsor: Universidade Ceuma • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New hand therapy may ease pain for arthritis patients with sensitive nerves
Symptom relief OngoingThis study looks at whether adding desensitization exercises to the usual hand rehab program can help rheumatoid arthritis patients who have central sensitization—a condition where the nervous system is extra sensitive to pain. About 81 adults with mild-to-moderate RA will be spl…
Phase: NA • Sponsor: Fulya Coşkun • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Can brain zaps boost social skills in kids with autism?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether 80 sessions of a gentle brain stimulation technique called tDCS, given over 12 months, can improve attention, social skills, and language in 180 children aged 6 to 11 who have autism along with rare diseases, genetic problems, or PANDAS. The treatment is …
Phase: PHASE1 • Sponsor: Spanish Foundation for Neurometrics Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New app aims to help type 1 diabetes patients exercise safely
Symptom relief ENROLLING_BY_INVITATIONThis study tests a smartphone app called PACTAID in 20 adults with type 1 diabetes. The app gives real-time advice during exercise to help keep blood sugar levels stable while using an automated insulin pump. Researchers will check if the app improves glucose control during and a…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Brain zaps and VR games: a new hope for MS symptoms?
Symptom relief OngoingThis study tests whether combining transcranial magnetic stimulation (TMS) with virtual reality exercises and physical therapy can improve symptoms like balance, fatigue, and thinking in people with multiple sclerosis. Thirty participants will receive both real and sham TMS in a …
Phase: NA • Sponsor: University of Sao Paulo • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Gluten-Free diet may ease Hashimoto's symptoms, study finds
Symptom relief OngoingThis study looks at whether a gluten-free diet can improve quality of life for people with Hashimoto's hypothyroidism who still have symptoms like brain fog and fatigue despite standard thyroid medication. About 50 adults with Hashimoto's will follow a gluten-free diet, and resea…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Can VR help MS patients with dizziness? trial planned but withdrawn
Symptom relief TerminatedThis pilot study aimed to test whether immersive virtual reality (VR) exercises could help people with multiple sclerosis who experience dizziness, balance issues, and fatigue. Participants would have been randomly assigned to either VR-based vestibular rehab or conventional exer…
Phase: NA • Sponsor: Maria Jesus Casuso-Holgado • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Brain zaps and workouts: new hope for MS fatigue?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a home exercise program combined with a gentle brain stimulation technique (tDCS) can reduce fatigue in people with multiple sclerosis. Sixty participants will either get real tDCS or a sham version alongside their exercises. The goal is to see if the com…
Phase: NA • Sponsor: Jacobo Formigo • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can an online course keep arthritis patients working?
Symptom relief OngoingThis study tests an online program designed to help people with inflammatory arthritis remain employed. The program includes eLearning modules, group video sessions, and consultations with an occupational therapist and vocational counselor. About 528 participants from three Canad…
Phase: NA • Sponsor: University of British Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Can an online class sharpen your mind with scleroderma?
Symptom relief OngoingThis study tests an 8-week online group program designed to help people with scleroderma improve their thinking skills and overall well-being. Researchers will compare participants who take the program right away to those on a waitlist. The goal is to see if the program boosts me…
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
App and talk therapy aim to ease diabetes distress in kids
Symptom relief OngoingThis study tests whether a program that combines a smartphone app with face-to-face therapy sessions can improve psychological well-being in children and adolescents with type 1 diabetes. The goal is to reduce diabetes-related distress and help young patients better manage their …
Phase: NA • Sponsor: Maimónides Biomedical Research Institute of Córdoba • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
ThyMoves study: exercise may ease thyroid symptoms and prevent falls in seniors
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether a tailored exercise program can improve quality of life, muscle strength, and balance in women aged 65 and older with Hashimoto's thyroiditis or multinodular toxic goiter. Participants will be randomly assigned to either the exercise program or usual c…
Phase: NA • Sponsor: Aalborg University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New hope for MS brain fog: personalized therapy shows promise
Symptom relief OngoingThis study tests a cognitive rehabilitation program called CIRCuiTS, adapted for people with Multiple Sclerosis (MS). Twenty-four participants will either start the program right away or after a 13-week wait. The program involves up to 36 hours of therapist-led and independent se…
Phase: NA • Sponsor: King's College London • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New program aims to help seniors master glucose monitors
Symptom relief OngoingThis study tests a remote education program called REST, designed to help adults aged 65 and older with insulin-treated diabetes start and keep using continuous glucose monitors (CGMs). The goal is to reduce dangerous low blood sugar episodes and improve overall glucose control. …
Phase: NA • Sponsor: Joslin Diabetes Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New app aims to keep MS patients on their feet
Symptom relief OngoingThis study tests a personal health app called MS FIT that lets people with multiple sclerosis log falls and near-falls, view their health data, and share it with their doctor. The goal is to improve communication about fall risks and provide educational tips. About 100 participan…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Lupus fatigue fight: coaching shows promise
Symptom relief OngoingThis study tests whether personalized coaching on physical activity and nutrition can reduce fatigue in people with lupus. 200 participants are split into two groups: one gets coaching on exercise and diet, the other gets general lupus education. The goal is to see if the coachin…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can a better diet ease MS symptoms? new study tests diet quality and calorie cutting
Symptom relief OngoingThis study looks at whether improving diet quality and reducing calories can help physical function, thinking, pain, fatigue, mood, and anxiety in 100 adults with relapsing-remitting or secondary progressive multiple sclerosis. Participants receive prepared meals and behavioral s…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Home-Based balance training shows promise for MS and Parkinson's patients
Symptom relief OngoingThis study tests whether a 4-week telerehabilitation program can improve balance and quality of life in 36 people with multiple sclerosis or Parkinson's disease. Participants do balance exercises at home while monitored by a hospital physiotherapist. The results are compared to s…
Phase: NA • Sponsor: IRCCS San Camillo, Venezia, Italy • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Can a computer program help MS patients sleep better?
Symptom relief OngoingThis study tests whether a 9-week online cognitive behavioral therapy program can improve sleep in people with multiple sclerosis (MS). About 550 participants in Norway will either receive the digital therapy or digital education about insomnia. The main goal is to see if the the…
Phase: NA • Sponsor: St. Olavs Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Healthy habits program aims to ease MS fatigue and boost Well-Being
Symptom relief OngoingThis study tests whether educational programs about exercise, Mediterranean diet, and mental strategies can improve quality of life and reduce fatigue in women with relapsing-remitting multiple sclerosis. About 60 participants will be assigned to either supervised in-person sessi…
Phase: NA • Sponsor: Universidad de Almeria • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Cycle-Smart workouts may ease MS fatigue
Symptom relief OngoingThis study looks at whether strength training done during a specific phase of the menstrual cycle can reduce fatigue and improve quality of life in women with relapsing-remitting multiple sclerosis. Twenty women with MS and a matched group without MS will take part. Researchers w…
Phase: NA • Sponsor: Universidad de Almeria • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can remote foot exercises ease arthritis pain?
Symptom relief TerminatedThis study tests whether foot core exercises done at home via video calls can reduce pain and improve walking in people with rheumatoid arthritis. Eighteen adults will be split into two groups: one gets live video sessions, the other gets recorded exercises. The goal is to see if…
Phase: NA • Sponsor: Pamukkale University • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Ancient chinese exercise tested for MS symptom relief
Symptom relief OngoingThis study compares qigong exercises to standard physical therapy for people with multiple sclerosis. Thirty-six adults with mild to moderate MS will do either qigong or conventional rehab three times a week. Researchers will measure changes in balance, mood, and overall well-bei…
Phase: NA • Sponsor: Baskent University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Could a rapamycin cream help bring back skin color in vitiligo?
Symptom relief OngoingThis study tests whether a cream containing rapamycin, applied daily for six months, can help restore skin color in people with vitiligo. Twenty participants aged 13 and older with nonsegmental vitiligo will apply the cream to one patch of skin and a placebo to another. The goal …
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Metaverse therapy: could virtual cooking and escape rooms heal the brain?
Symptom relief OngoingThis study tests a set of virtual reality exergames in the Metaverse to help people with neurological conditions like multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury improve their cognitive skills. 25 participants will try games like virtual cooking an…
Phase: NA • Sponsor: Istituto per la Ricerca e l'Innovazione Biomedica • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Poop pills could ease stomach troubles for scleroderma patients
Symptom relief OngoingThis study tests whether fecal microbiota transplantation (FMT) – giving healthy donor stool in capsules – can safely reduce chronic diarrhea in people with systemic sclerosis. Twenty adults with scleroderma and persistent diarrhea will receive either FMT or a placebo. The main g…
Phase: NA • Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Pre-Exercise drink may shield teens with diabetes from dangerous sugar drops
Symptom relief TerminatedThis study aimed to see if a corn-starch based drink taken before exercise could lower the risk of delayed low blood sugar in teens with type 1 diabetes. It also looked at whether it could improve biking performance. The study was withdrawn before enrolling any participants, so n…
Phase: NA • Sponsor: State University of New York at Buffalo • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
New wearable device aims to tackle MS bladder issues from home
Symptom relief OngoingThis study tests whether a wearable device, used at home alongside pelvic floor therapy, can help people with multiple sclerosis manage bladder problems. Twenty women with MS will use the device for three months. The main goal is to see if the approach is practical and easy to us…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Fatigue study seeks to unravel mystery of exhaustion
Knowledge-focused OngoingThis study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …
Sponsor: National Center for Complementary and Integrative Health (NCCIH) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Eye tests could spot silent vision damage in lupus patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study investigates whether people with systemic lupus erythematosus (SLE) show early signs of retinal damage before they notice any vision problems. Researchers will use advanced eye imaging and vision tests to compare lupus patients with healthy volunteers. The goal is to f…
Sponsor: The First Affiliated Hospital of Anhui Medical University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Simple squeeze exercise may ease arthritis pain, study hints
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a simple isometric (static) hand exercise can change how people with rheumatoid arthritis feel pain. Researchers will measure pain tolerance, pressure thresholds, and muscle oxygen levels in 66 adults. The goal is to see if this type of exercise can help …
Phase: NA • Sponsor: Zülal TATAR • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a blood test predict lupus flares? new study aims to find out
Knowledge-focused OngoingThis study follows 25 adults with inactive lupus to see if blood samples can predict when a flare will happen. Researchers will analyze genes and other molecules to find patterns linked to flare risk. The goal is to develop tools that help doctors personalize treatment and preven…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
MS drug levels in breast milk under study for nursing moms
Knowledge-focused OngoingThis study looks at how much of the multiple sclerosis drug ofatumumab gets into breast milk. About 24 women with relapsing MS who are breastfeeding and starting or restarting ofatumumab will provide milk samples. The goal is to measure drug concentrations, which may help guide f…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New vitiligo registry aims to uncover disease trends in 2,500 patients
Knowledge-focused ENROLLING_BY_INVITATIONThis observational registry will follow 2,500 adults and adolescents with nonsegmental vitiligo to understand how the disease presents and progresses over time. Participants continue their usual care with a dermatologist. No experimental treatment is given; the goal is to collect…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists probe immune secrets of four skin diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to see if patient diaries match insurance data
Knowledge-focused TerminatedThis study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive medicare study aims to improve joint replacement safety
Knowledge-focused OngoingThis study looks at records from over 500,000 Medicare beneficiaries with rheumatoid arthritis or ankylosing spondylitis who had major orthopedic procedures like joint replacements or spine surgery between 1999 and 2015. Researchers want to understand how often complications happ…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lupus care under the microscope: new registry tracks Real-World treatment in kazakhstan
Knowledge-focused OngoingThis study is a registry that will follow about 500 adults with lupus (SLE) in Kazakhstan to see how the disease behaves and how doctors treat it in everyday practice. Researchers will look at disease activity, organ damage, and which medications are used. No new treatments are b…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
MS drug use in pregnancy under the microscope: is it safe for baby?
Knowledge-focused OngoingThis study looks at how many women with multiple sclerosis (MS) use the drug interferon-beta during the second and third trimesters of pregnancy in Finland and Sweden. Researchers want to know if there are enough cases to study whether the drug affects pregnancy outcomes like bir…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for clues to predict blistering disease severity
Knowledge-focused OngoingThis study looks at 50 people with bullous pemphigoid, a skin condition that causes blisters. Researchers want to see if certain proteins in skin samples and blood markers like IgE and eosinophil counts are linked to how severe the disease is. The goal is to find better ways to m…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test could predict MS Flare-Ups, study hopes
Knowledge-focused OngoingThis study looks at whether a blood test measuring a protein called neurofilament light (sNfL) can help doctors predict and manage disease activity in people with relapsing multiple sclerosis (MS). About 489 adults with MS in Germany will be observed for 24 months. The goal is to…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Breathing in xenon: a new MRI scan to see lung damage?
Knowledge-focused OngoingThis study at Duke University tests whether a special MRI scan using inhaled xenon gas can detect changes in lung function over time in people with progressive pulmonary fibrosis. Sixty adults with various types of lung scarring will have MRI scans before starting anti-fibrotic m…
Phase: PHASE2 • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Major study tracks Real-World MG care in china
Knowledge-focused OngoingThis study follows about 1,200 people with myasthenia gravis (MG) across China to understand how the disease is treated in real-world clinics. Researchers will track symptoms, daily living abilities, quality of life, and healthcare use every 6 months until 2027. The goal is to le…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Gut check: 4,000-Person study links diet, genes, and stomach troubles
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how diet, genetics, and gut bacteria work together to cause digestive problems like IBS, IBD, and celiac disease. Researchers will follow about 4,000 adults with and without these conditions to find patterns. The goal is to understand why some people get sick …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive italian MS registry aims to unlock secrets of the disease
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…
Sponsor: Fondazione Italiana Sclerosi Multipla • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Researchers track Real-World side effects of ofev in lung disease patients
Knowledge-focused OngoingThis study monitors the long-term safety of the drug Ofev in people with lung disease caused by scleroderma. Researchers are tracking side effects like diarrhea and nausea in 586 patients in Japan who are starting Ofev for the first time. The goal is to see how common these side …
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
MS drug safety in pregnancy under scrutiny: new study tracks birth outcomes
Knowledge-focused OngoingThis study observes over 1,100 pregnant women with multiple sclerosis to see if taking the drug diroximel fumarate (VUMERITY) affects their babies' health. Researchers will compare birth defects, miscarriages, preterm births, and stillbirths among women who took DRF, other MS dru…
Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Psoriatic arthritis drug showdown: which treatment do patients stick with?
Knowledge-focused OngoingThis study follows over 1,300 people with psoriatic arthritis who are starting either guselkumab (Tremfya) or an IL-17 inhibitor as part of their routine care. Researchers will track how long patients continue each treatment and monitor joint swelling and tenderness. The goal is …
Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Massive psoriasis registry tracks drug safety over years
Knowledge-focused OngoingThis study is a large registry that follows nearly 16,000 people with psoriasis to monitor the long-term safety of several treatments, including biologic drugs like infliximab and ustekinumab. Participants receive their usual care while researchers track side effects, disease act…
Sponsor: Janssen Scientific Affairs, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Your iPhone could help monitor psoriasis: new study tests smartphone tracking
Knowledge-focused OngoingThis study uses an iPhone app to track symptoms of psoriasis and psoriatic arthritis in 1,000 adults. Participants complete surveys, take photos of their skin, and use phone sensors to measure joint function. The goal is to see if smartphones can reliably monitor these conditions…
Sponsor: Sage Bionetworks • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Period power: study reveals how hormones impact blood sugar control
Knowledge-focused OngoingThis study looks at how the menstrual cycle changes blood sugar and energy use in women with type 1 diabetes. About 40 women will use a closed-loop insulin pump and continuous glucose monitor to track these changes. The goal is to understand how hormone shifts affect insulin need…
Sponsor: Lia Bally • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New imaging technique could reveal hidden brain inflammation
Knowledge-focused TerminatedThis study tests a new imaging method to see if white blood cells enter the brain in people with multiple sclerosis, fibromyalgia, or chronic fatigue syndrome. Participants receive their own white blood cells tagged with a radioactive tracer, then undergo a brain PET/MRI scan. Th…
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Blood protein may reveal clues about ankylosing spondylitis
Knowledge-focused OngoingThis study looks at a protein called progranulin in the blood of people with ankylosing spondylitis (a type of arthritis that affects the spine) and compares it to healthy volunteers. Researchers want to see if progranulin levels are linked to disease activity and whether they ch…
Sponsor: Kirsehir Ahi Evran Universitesi • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
MS t cell study pulled before starting
Knowledge-focused TerminatedThis study aimed to compare T cell populations between people with multiple sclerosis and healthy controls to better understand which immune cells attack the nerves. It was withdrawn before enrolling any participants, so no results are available. The goal was to learn more about …
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New digital tool aims to simplify care for seniors with multiple conditions
Knowledge-focused OngoingThis study tests a web-based tool called gp-multitool.de that helps general practitioners follow guidelines for older patients with multiple chronic conditions. About 659 patients from GP practices in Germany are taking part. The tool lets patients fill out questionnaires online …
Phase: NA • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Hidden heart risk in kids with diabetes: new study investigates
Knowledge-focused OngoingThis study examines how common cardiac autonomic neuropathy (nerve damage affecting the heart) is in children and teens with type 1 diabetes. Researchers will monitor 75 participants using heart tests and check if longer diabetes duration or poor blood sugar control raises the ri…
Phase: NA • Sponsor: Marwa Abouelela Abd Elsalam • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Hidden liver risk in type 1 diabetes revealed by new scan
Knowledge-focused OngoingThis study looks at how often people with type 1 diabetes have fatty liver disease and serious liver scarring. Researchers used a special ultrasound and blood tests to check 533 adults. The goal is to find high-risk patients who need a liver specialist.
Sponsor: Joslin Diabetes Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Brain scans may predict who gets long-term pain from arthritis
Knowledge-focused OngoingThis study looks at why some people with early rheumatoid arthritis develop long-lasting chronic pain while others do not. Researchers will use pain sensitivity tests and brain scans to find clues. The goal is to better understand the transition from acute to chronic pain, which …
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New MRI study seeks hidden stroke causes in rare blood disorder
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at why people with antiphospholipid syndrome (APS) — a condition that raises blood clot risk — may have narrowed brain arteries. Researchers will use advanced MRI scans on 60 APS patients to check for artery narrowing and plaque buildup. The goal is to better und…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Can we predict who will benefit from cladribine? new study aims to find out
Knowledge-focused OngoingThis observational study follows 367 adults with relapsing multiple sclerosis who are taking cladribine tablets (Mavenclad) in routine care. Researchers want to find out which patient characteristics predict how long people stay on the drug and how well it works. The goal is to h…
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study probes why kidney disease still strikes in type 1 diabetes
Knowledge-focused OngoingThis study looks at why up to 40% of people with type 1 diabetes develop kidney disease, even with better blood sugar control. Researchers will use kidney biopsies and advanced imaging in 100 adults to find hidden risk factors like insulin resistance and inflammation. The goal is…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Researchers hunt for clues: do our own antibodies harm nerves?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether the immune system mistakenly makes antibodies that attack the body's own nerves and muscles in people with multiple sclerosis, myasthenia gravis, and similar conditions. Researchers will collect blood samples (and sometimes cheek swabs) from 120 adults…
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Doctor education may boost use of cheaper biologic drugs
Knowledge-focused OngoingThis study looks at whether offering doctors educational meetings about biosimilar medications leads them to prescribe more of these lower-cost alternatives instead of the original brand-name drugs. About 1,325 clinicians who prescribe adalimumab for conditions like rheumatoid ar…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Does an extra knee ligament procedure lead to arthritis later?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 510 people who had ACL knee reconstruction surgery, with or without an extra procedure called LET, about 10 years ago. Researchers want to see if adding LET increases the chance of developing knee osteoarthritis. Participants will get X-rays and answer question…
Phase: NA • Sponsor: Western University, Canada • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Scottish MS study aims to predict disease course years in advance
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 440 people with relapsing-remitting multiple sclerosis for 5 to 10 years after their diagnosis. Researchers will use brain scans, lab tests, and genetic information to find patterns that predict how the disease will progress. The goal is to help doctors and pat…
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Nerve pain linked to poor sleep in ankylosing spondylitis patients
Knowledge-focused OngoingThis study investigates how common spinal nerve pain is in people with ankylosing spondylitis (AS) and whether it affects their sleep. Researchers will use questionnaires to assess pain, sleep quality, quality of life, and fatigue in 292 AS patients. The goal is to better underst…
Sponsor: Bozyaka Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Eye scans and movement tests could revolutionize MS monitoring
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing two new digital tools to monitor how multiple sclerosis (MS) progresses over time. One tool uses cameras to measure movement and balance, while the other uses eye scans to detect nerve damage. Ten people with stable MS will try these tools, and the results w…
Sponsor: University of Exeter • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Researchers probe hidden nerve pain in ankylosing spondylitis
Knowledge-focused OngoingThis study looks at nerve-related pain in people with ankylosing spondylitis, a type of arthritis that mainly affects the spine. Researchers will use a questionnaire to describe the pain and see how it relates to daily activities. About 130 adults with the condition will take par…
Sponsor: Bozyaka Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Mailed quiz could spot hidden arthritis in psoriasis patients
Knowledge-focused OngoingThis study tests whether sending a short screening questionnaire directly to people with psoriasis can help detect psoriatic arthritis earlier. 18,000 participants will be randomly assigned to receive the questionnaire or not. Those with high scores will be advised to see a rheum…
Phase: NA • Sponsor: Jessica Walsh • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
MS drug shot study tracks immune reactions
Knowledge-focused OngoingThis study tracks about 400 people with multiple sclerosis (MS) to see how many develop antibodies against the drug natalizumab when it is given as a shot under the skin. Researchers will also look at side effects and relapse rates in those who develop antibodies. The goal is to …
Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Could a clogged brain drain trigger MS? new MRI study investigates
Knowledge-focused OngoingThis pilot study uses special MRI scans to check if the brain's waste-clearing system, called the glymphatic system, is not working properly in people with Clinically Isolated Syndrome (CIS), which is often the first sign of Multiple Sclerosis (MS). Researchers will compare scans…
Sponsor: University of Exeter • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
AI listens to your voice to spot diabetes stress
Knowledge-focused TerminatedThis study explores whether artificial intelligence can detect stress in people with type 1 diabetes by analyzing their voice recordings. Participants record their voice four times a day for a period. The goal is to develop a tool that helps patients and doctors better understand…
Phase: NA • Sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New registry aims to unlock safer pregnancies for women with autoimmune conditions
Knowledge-focused ENROLLING_BY_INVITATIONThis registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Smartphone app tracks stress to uncover diabetes blood sugar mystery
Knowledge-focused TerminatedThis study looks at how everyday stress impacts blood sugar levels in people with type 1 diabetes. Researchers will ask 125 participants to rate their stress four times a day using a smartphone app, while a continuous glucose monitor tracks their blood sugar. The goal is to see i…
Phase: NA • Sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Tiny study peers inside finger joints to unlock RA bone erosion secrets
Knowledge-focused OngoingThis study looks at bone erosions in the finger joints of 9 people with rheumatoid arthritis. Researchers use advanced imaging and tissue analysis to see tiny blood vessels and bone structure. The goal is to better understand how joint damage happens, which could lead to better m…
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Sjögren's study dives deep into immune clues in spit and blood
Knowledge-focused OngoingThis study looks at immune system markers in the saliva and blood of 80 people with primary Sjögren's syndrome, a chronic disease causing dry eyes and mouth. Researchers will check for antibodies that may block a key enzyme and see how gum disease affects symptoms. The goal is to…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New hip cup under observation: will it last?
Knowledge-focused OngoingThis study is observing 60 people who received a special hip replacement cup (Plasmafit Revision Structan) during routine surgery. Researchers are checking how well the cup works and how long it lasts by tracking hip function and any need for repeat surgery. No new treatment is b…
Sponsor: Aesculap AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scleroderma biomarker study pulled before start
Knowledge-focused TerminatedThis study planned to collect extra blood and urine samples from scleroderma patients during their regular check-ups to find biological markers that could predict if their disease would get worse over the next 10 years. The goal was to improve treatment decisions and identify the…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New scan could reveal hidden joint inflammation in arthritis patients
Knowledge-focused TerminatedThis early study tests a radioactive imaging agent called 89Zr-Cimzia in 10 people with rheumatoid arthritis. The goal is to see if it can highlight inflamed joints on a PET scan, comparing painful joints to pain-free ones. The study is currently suspended, and it is exploratory,…
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New program aims to improve pregnancy care for women with lupus
Knowledge-focused OngoingThis study tests a program called HOP-STEP that helps doctors talk about pregnancy planning with women who have lupus. The goal is to make sure doctors document contraception use and pregnancy intentions during visits. The study involves 14 participants and is being tested at two…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
MS swallowing woes linked to muscle loss, new study probes connection
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how swallowing difficulties in people with multiple sclerosis (MS) relate to their nutrition and muscle function. Researchers will assess 34 ambulatory MS patients using questionnaires and physical tests. The goal is to better understand these connections to i…
Sponsor: Sanko University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can online chats help latinx teens master diabetes tech?
Knowledge-focused OngoingThis study tests whether virtual peer groups can help Latinx teenagers with type 1 diabetes use insulin pumps and continuous glucose monitors more effectively. About 120 teens and their caregivers will join online sessions covering topics like family relationships, school, and wo…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Could your diet ward off arthritis? UK biobank study investigates
Knowledge-focused OngoingThis study looks at how different eating habits—like being a vegetarian, eating fish, or drinking alcohol—might affect a person's chance of developing rheumatoid arthritis. Researchers are using data from half a million UK adults aged 40 to 70. They are not testing a new treatmen…
Sponsor: University of Leeds • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New ultrasound technique could improve how we monitor scleroderma in kids
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether a special ultrasound called elastography can measure changes in skin stiffness in children with localized scleroderma (morphea). The goal is to find a better, non-invasive way to track how well treatment is working. About 20 children and teens will be …
Sponsor: The Hospital for Sick Children • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Brain scan breakthrough could spot MS cognitive decline early
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing whether a new type of MRI can detect changes in the brain that lead to memory and thinking problems in people with multiple sclerosis (MS). Researchers will scan 75 adults with MS and give them thinking and memory tests. The goal is to see if the new MRI mea…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Childhood obesity linked to worse MS brain damage?
Knowledge-focused OngoingThis study looks at whether obesity makes multiple sclerosis (MS) worse in children. Researchers will compare brain scans and blood markers between normal-weight and overweight/obese kids recently diagnosed with MS. The goal is to understand how obesity might drive inflammation a…
Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
French study tracks daily life changes in MS patients on newer drug
Knowledge-focused OngoingThis study follows 302 adults with multiple sclerosis in France who are starting the drug ofatumumab as part of their normal care. Researchers will measure how patients' quality of life changes after 12 months using a special questionnaire. The goal is to understand real-world be…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New study sheds light on thyroid disease in kids under 6
Knowledge-focused ENROLLING_BY_INVITATIONThis study examines autoimmune hyperthyroidism in children diagnosed before age 6, focusing on their symptoms, growth, and response to treatment. Researchers will compare these young children with older children who have the same condition. The goal is to identify patterns that c…
Sponsor: IRCCS Ospedale San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New registry aims to unlock secrets of rare blood disorder
Knowledge-focused OngoingThis study is a registry that collects information from about 429 adults with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS), a rare condition where the immune system attacks red blood cells in cold temperatures. Researchers will track symptoms, treatments, compl…
Sponsor: RECORDATI GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Virtual reality vs. slideshow: which teaches nursing students more about MS?
Knowledge-focused OngoingThis study tested two teaching methods for nursing students: a 360-degree video experience about the brain and multiple sclerosis (MS), and a standard slideshow with the same information. About 50 students from three nursing schools took part. Researchers measured how much they l…
Phase: NA • Sponsor: Hunter College of City University of New York • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC
-
Can a phone app help people with Parkinson's and MS stay active?
Knowledge-focused OngoingThis study follows 200 people with Parkinson's disease or multiple sclerosis over one year to see how active they are. Participants use a smartphone app called Datos Health to track steps, workouts, and heart rate. A physical therapist sets personalized exercise goals. The goal i…
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
New screening study targets hidden diabetes and celiac disease in High-Risk communities
Knowledge-focused OngoingThis study is screening 115 underserved children and adults who are at risk for type 1 diabetes or celiac disease. Researchers will use blood tests to find early signs of these conditions, aiming to improve how we detect them. The goal is to catch these diseases sooner, especiall…
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
New study links blood sugar levels to heart risks in type 1 diabetes
Knowledge-focused OngoingThis study looks at how well blood sugar is controlled and how diet relates to heart health in people with type 1 diabetes. Researchers will study 90 patients who use the MiniMed 780G insulin pump. They will measure blood sugar patterns, diet quality, and markers of heart and blo…
Sponsor: Attikon Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Scientists hunt for blood clues to predict arthritis flares
Knowledge-focused OngoingThis study follows 25 adults with rheumatoid arthritis for one year to see how their blood samples relate to changes in disease activity. The goal is to find early warning signs of a flare. Participants give blood at several visits while their joint swelling and inflammation are …
Sponsor: Rockefeller University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New program aims to ease diabetes care transition for teens
Knowledge-focused OngoingThis study tests a program called SHIFT2 that helps teens and young adults with type 1 diabetes prepare for the switch from pediatric to adult medical care. Participants work with a transition coach and receive messages to encourage self-management. The goal is to see if this sup…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
MS and periods: new study tracks symptom patterns
Knowledge-focused TerminatedThis study looks at how multiple sclerosis (MS) symptoms, like fatigue and thinking skills, change during different phases of the menstrual cycle. About 300 females with MS who still have periods will track their symptoms using a phone app for six months. The goal is to find patt…
Sponsor: University of Alberta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Brain scans reveal why some diabetics miss danger signs
Knowledge-focused OngoingThis study uses brain imaging to understand why some people with type 1 diabetes lose their ability to sense dangerously low blood sugar. Researchers will temporarily induce low blood sugar in participants and scan their brains to see how glucose levels change. The goal is to lea…
Phase: NA • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Brain pacemaker study seeks better patterns for movement disorders
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how different patterns of deep brain stimulation (DBS) affect movement symptoms and brain activity in people with Parkinson's disease, essential tremor, multiple sclerosis, or dystonia. Researchers will test non-regular stimulation patterns to find ways to mak…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New study observes patients getting nasal stem cell therapy for brain conditions
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…
Sponsor: Healing Hope International • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
MS app study pulled before it even started
Knowledge-focused TerminatedThis study aimed to test whether a smartphone app could track multiple sclerosis (MS) symptoms and progression remotely. It planned to enroll adults with MS across different countries to see if digital measurements matched standard clinical tests. However, the study was withdrawn…
Sponsor: Research Center for Clinical Neuroimmunology and Neuroscience Basel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New hip implant under observation: will it stand the test of time?
Knowledge-focused OngoingThis study follows 248 adults receiving a CoreHip hip replacement to see how their hip function, pain, and leg length change over time. Participants are treated as part of routine care, and no extra tests or treatments are given. The goal is to collect real-world data on the impl…
Sponsor: Aesculap AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Could a common Weight-Loss drug shield the brain? early trial launches
Knowledge-focused TerminatedThis pilot study tests whether liraglutide (Saxenda), a weight-loss drug, can raise levels of a brain-protective protein called BDNF in 30 people with multiple sclerosis, long-COVID, or leukemia who are overweight and have memory or concentration problems. Participants will injec…
Phase: EARLY_PHASE1 • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists hunt for hidden clues in adult diabetes
Knowledge-focused OngoingThis study aims to find new biological markers (biomarkers) for Adult Onset Autoimmune Diabetes (AOnAD) by analyzing blood samples from 25 adults with type 1 diabetes. Researchers will measure changes in specific microRNAs from tiny particles in the blood. No treatment is given; …
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Hidden hunger in MS: new study probes link between malnutrition and disability
Knowledge-focused OngoingThis observational study measures how common malnutrition is in people with relapsing-remitting multiple sclerosis (RRMS) and whether it is linked to disability. Researchers will assess nutritional status, body composition, and other factors like depression and incontinence in 16…
Sponsor: Antalya Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused TerminatedThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Can a quick sleep check help teens with diabetes?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether doctors can easily screen for sleep problems in teens with type 1 diabetes during regular clinic visits. About 50 teens who use a continuous glucose monitor will take part. The goal is to see how often doctors can complete the sleep discussion and foll…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Tiny study probes why MS drug may miss hidden immune cells
Knowledge-focused ENROLLING_BY_INVITATIONThis study will examine lymph nodes from 5 people with relapsing-remitting multiple sclerosis who are starting ocrelizumab treatment. The goal is to see how effectively the drug removes B cells from lymph nodes, since these cells are known to be important in MS but are not well s…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Study aims to boost diabetes tech access for underserved kids
Knowledge-focused TerminatedThis study was designed to learn why some children with type 1 diabetes, especially those with public insurance, do not use helpful diabetes technology like continuous glucose monitors. Researchers planned to interview and survey healthcare providers to understand barriers and fi…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Walking study for Parkinson's and stroke patients withdrawn before starting
Knowledge-focused TerminatedThis study was designed to test a wearable sensor system that tracks how people walk on different surfaces like grass, pavement, and stairs. It aimed to include healthy volunteers and people with conditions such as Parkinson's disease, dementia, stroke, multiple sclerosis, or low…
Sponsor: University of Leeds • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Smart insoles could revolutionize MS monitoring at home
Knowledge-focused OngoingThis study tests a smart insole and phone app that track walking patterns in people with multiple sclerosis (MS). The goal is to see if this wearable device can reliably detect changes in a person's condition during daily life. 90 adults with MS will use the device at home for 6 …
Sponsor: Celestra Health Systems • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Could your menstrual cycle affect MS symptoms? new study investigates
Knowledge-focused OngoingThis study looks at how natural hormone changes during the menstrual cycle impact brain-to-muscle communication, learning new motor skills, and fatigue in women with multiple sclerosis. Researchers will measure these factors at different cycle phases in 14 participants. The goal …
Sponsor: Milap Sandhu • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
15,000 skin patients enrolled in massive Real-World treatment study
Knowledge-focused OngoingThis study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New study checks if hand disability survey works for turkish scleroderma patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to see if a questionnaire called HDISS-DU, which measures hand disability caused by digital ulcers in people with systemic sclerosis (scleroderma), is valid and reliable in Turkish. About 72 adults with scleroderma will fill out the questionnaire along with other …
Sponsor: Pamukkale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New hand health survey for scleroderma patients tested in turkish
Knowledge-focused ENROLLING_BY_INVITATIONThis study checks if a questionnaire called the Hand ScleroDerma Lived Experience Scale (HAnDE Scale) works well for Turkish-speaking people with systemic sclerosis. Researchers will ask 54 participants to fill out the survey and perform hand movement tests. The goal is to make s…
Sponsor: Pamukkale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Massive diabetes biobank aims to predict kidney and heart risks
Knowledge-focused OngoingThis study is building a large biobank of health information and blood samples from 48,000 people with diabetes in Hong Kong. Researchers will analyze genetic and other markers to find better ways to predict serious complications like kidney failure, heart disease, and stroke. Th…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Scientists hunt for clues to MS severity
Knowledge-focused OngoingThis study aims to find a combination of markers—from genetics, immune system, and brain scans—that are linked to how severe multiple sclerosis (MS) becomes. Researchers will follow 120 people with MS and their siblings who also have the condition. Participants undergo neurologic…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Phone app could revolutionize MS monitoring
Knowledge-focused OngoingThis study tests whether smartphone-based challenges and surveys can reliably measure multiple sclerosis (MS) progression. Researchers will compare these digital biomarkers with standard clinical exams, brain scans, and lab tests in 300 people with MS over two years. The goal is …
Sponsor: Research Center for Clinical Neuroimmunology and Neuroscience Basel • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Walking and thinking at the same time: new study tests dual-task ability in MS patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether the Timed Up and Go (TUG) test, a common walking test, can reliably measure how people with multiple sclerosis (MS) perform when they have to walk and think at the same time. Fifty volunteers with MS will do the TUG test alone, while counting backwards…
Sponsor: Sanko University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can a simple sensor replace finger pricks for kids in the hospital?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether continuous glucose monitors (CGMs) are practical for youth aged 2 to 26 with high blood sugar during hospital stays. Researchers will compare CGM readings with standard finger-stick tests and ask patients, families, and nurses about their experience us…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Pregnancy and diabetes: new study tracks insulin changes
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to understand how the body's response to insulin changes during pregnancy in people with type 1 diabetes. Researchers will analyze data from continuous glucose monitors and insulin pumps used by 100 participants from before pregnancy to six months after birth. The…
Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Could a breathing trick plus mild zaps strengthen brain pathways in MS?
Knowledge-focused OngoingThis study looks at whether combining a special breathing technique (called acute intermittent hypoxia, or AIH) with mild electrical stimulation of leg muscles can boost brain-to-muscle signals in people with relapsing forms of multiple sclerosis. About 40 participants will have …
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Fatty liver and psoriasis study pulled before it started
Knowledge-focused TerminatedThis study aimed to understand the link between non-alcoholic fatty liver disease (NAFLD) and psoriatic disease (psoriasis and psoriatic arthritis) in overweight adults. Researchers planned to use the drug guselkumab (Tremfya) to see if it improved both conditions. However, the t…
Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC